View Filing Data

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2019

Transaction-related expenses represent costs primarily related to termination, restructuring, strategic review, management transition and other acquisition-related costs. Transaction-related expenses comprised the following costs for the years ended years ended December 31, 2019, 2018 and 2017 (in thousands):

	Year Ended December 31,
	2019		2018		2017
Termination, restructuring and strategic review costs	$	18,233	$	16,785	$	19,469
Management transition costs		5,529		14,033		—
Legal, accounting and other acquisition-related costs		3,302		3,689		4,798
	$	27,064	$	34,507	$	24,267

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 124,192	$ 50,510
Accounts receivable, net	339,775	318,087
Other current assets	78,244	81,820
Total current assets	542,211	450,417
Property and equipment, net	3,224,034	3,107,766
Goodwill	2,449,131	2,396,412
Intangible assets, net	90,357	88,990
Deferred tax assets	3,339	3,468
Derivative instrument assets		60,524
Operating lease right-of-use assets	501,837
Other assets	68,233	64,927
Total assets	6,879,142	6,172,504
Current liabilities:
Current portion of long-term debt	43,679	34,112
Accounts payable	127,045	117,740
Accrued salaries and benefits	122,552	113,299
Current portion of operating lease liabilities	29,140
Other accrued liabilities	141,160	151,226
Total current liabilities	463,576	416,377
Long-term debt	3,105,420	3,159,375
Deferred tax liabilities	71,860	80,372
Operating lease liabilities	502,252
Derivative instrument liabilities	68,915
Other liabilities	128,587	154,267
Total liabilities	4,340,610	3,810,391
Redeemable noncontrolling interests	33,151	28,806
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,715,591 and 87,444,473 issued and outstanding as of December 31, 2019 and 2018, respectively	877	874
Additional paid-in capital	2,557,642	2,541,987
Accumulated other comprehensive loss	(414,884)	(462,377)
Retained earnings	361,746	252,823
Total equity	2,505,381	2,333,307
Total liabilities and equity	$ 6,879,142	$ 6,172,504

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Equity-based compensation expense	$ 17,307	$ 22,001	$ 23,467

Summary of Significant Accounting Policies - Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 23,708	$ 30,802
Other receivables	16,097	19,205
Cost report receivable	13,723	10,340
Workers’ compensation deposits – current portion	10,000	10,000
Income taxes receivable	5,579	2,380
Inventory	4,759	5,055
Insurance receivable - current portion	3,030	2,049
Other	1,348	1,989
Other current assets	$ 78,244	$ 81,820

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt	$ 4,821	$ 5,953
Less: unamortized debt issuance costs, discount and premium	(31,400)	(41,128)
Long-term debt	3,149,099	3,193,487
Less: current portion	(43,679)	(34,112)
Long-term debt	3,105,420	3,159,375
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loan [Member]
Debt Instrument [Line Items]
Senior Secured	346,750	365,750
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,338,928	1,372,912
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 390,000	$ 390,000

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2016	$ 2,167,724	$ 867	$ 2,496,288	$ (549,570)	$ 220,139
Balance, shares at Dec. 31, 2016		86,688,000
Common stock issued under stock incentive plans	$ 2,069	$ 4	2,065
Common stock issued under stock incentive plans, shares	87,367	372,000
Common stock withheld for minimum statutory taxes	$ (5,524)		(5,524)
Equity-based compensation expense	23,467		23,467
Cumulative effect of change in accounting principle	8,599				8,599
Other comprehensive income (loss)	175,452			175,452
Other	1,249		1,249
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	199,835				199,835
Balance at Dec. 31, 2017	2,572,871	$ 871	2,517,545	(374,118)	428,573
Balance, shares at Dec. 31, 2017		87,060,000
Common stock issued under stock incentive plans	$ 374	$ 3	371
Common stock issued under stock incentive plans, shares	20,989	384,000
Common stock withheld for minimum statutory taxes	$ (3,781)		(3,781)
Equity-based compensation expense	22,001		22,001
Other comprehensive income (loss)	(88,259)			(88,259)
Other	5,851		5,851
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	(175,750)				(175,750)
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018	87,444,473	87,444,000
Common stock issued under stock incentive plans	$ 569	$ 3	566
Common stock issued under stock incentive plans, shares	55,671	271,000
Common stock withheld for minimum statutory taxes	$ (2,218)		(2,218)
Equity-based compensation expense	17,307		17,307
Other comprehensive income (loss)	47,493			47,493
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	108,923				108,923
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	$ 2,557,642	$ (414,884)	$ 361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000

Leases - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jan. 01, 2019	Dec. 31, 2019
Lessee Lease Description [Line Items]
Right-of-use assets		$ 546,207
Lease liabilities		$ 581,873
Operating leases remaining lease term	1 year
ASU 2016-02 [Member]
Lessee Lease Description [Line Items]
Right-of-use assets	$ 500,300
Lease liabilities	$ 526,600
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		30 years
Copiers and Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		1 year
Copiers and Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract		3 years

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year.

Financial Information for the Company and Its Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	98,943	$	25,249	$	—		$	124,192
Accounts receivable, net		—		266,864		72,911		—			339,775
Other current assets		—		61,508		16,736		—			78,244
Total current assets		—		427,315		114,896		—			542,211
Property and equipment, net		—		1,313,830		1,910,204		—			3,224,034
Goodwill		—		1,992,344		456,787		—			2,449,131
Intangible assets, net		—		58,291		32,066		—			90,357
Deferred tax assets – noncurrent		1,403		—		3,339		(1,403	)		3,339
Operating lease right-of-use assets		—		97,396		404,441		—			501,837
Investment in subsidiaries		5,521,340		—		—		(5,521,340	)		—
Other assets		233,975		48,949		13,127		(227,818	)		68,233
Total assets	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142
Current liabilities:
Current portion of long-term debt	$	43,679	$	—	$	—	$	—		$	43,679
Accounts payable		—		87,165		39,880		—			127,045
Accrued salaries and benefits		—		89,483		33,069		—			122,552
Current portion of operating lease liabilities		—		17,967		11,173		—			29,140
Other accrued liabilities		33,323		22,672		85,165		—			141,160
Total current liabilities		77,002		217,287		169,287		—			463,576
Long-term debt		3,105,420		—		227,818		(227,818	)		3,105,420
Deferred tax liabilities – noncurrent		—		21,858		51,405		(1,403	)		71,860
Operating lease liabilities		—		85,365		416,887		—			502,252
Derivative instrument liabilities		68,915		—		—		—			68,915
Other liabilities		—		110,445		18,142		—			128,587
Total liabilities		3,251,337		434,955		883,539		(229,221	)		4,340,610
Redeemable noncontrolling interests		—		—		33,151		—			33,151
Total equity		2,505,381		3,503,170		2,018,170		(5,521,340	)		2,505,381
Total liabilities and equity	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	32,471	$	18,039	$	—		$	50,510
Accounts receivable, net		—		248,218		69,869		—			318,087
Other current assets		—		60,160		21,660		—			81,820
Total current assets		—		340,849		109,568		—			450,417
Property and equipment, net		—		1,219,803		1,887,963		—			3,107,766
Goodwill		—		1,936,057		460,355		—			2,396,412
Intangible assets, net		—		56,611		32,379		—			88,990
Deferred tax assets – noncurrent		1,841		—		3,468		(1,841	)		3,468
Derivative instruments		60,524		—		—		—			60,524
Investment in subsidiaries		5,190,771		—		—		(5,190,771	)		—
Other assets		306,495		52,824		9,548		(303,940	)		64,927
Total assets	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504
Current liabilities:
Current portion of long-term debt	$	34,112	$	—	$	—	$	—		$	34,112
Accounts payable		—		79,463		38,277		—			117,740
Accrued salaries and benefits		—		84,150		29,149		—			113,299
Other accrued liabilities		32,837		42,062		76,327		—			151,226
Total current liabilities		66,949		205,675		143,753		—			416,377
Long-term debt		3,159,375		—		303,940		(303,940	)		3,159,375
Deferred tax liabilities – noncurrent		—		31,874		50,339		(1,841	)		80,372
Other liabilities		—		107,866		46,401		—			154,267
Total liabilities		3,226,324		345,415		544,433		(305,781	)		3,810,391
Redeemable noncontrolling interests		—		—		28,806		—			28,806
Total equity		2,333,307		3,260,729		1,930,042		(5,190,771	)		2,333,307
Total liabilities and equity	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504

Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	1,882,518	$	1,224,944		$	—			3,107,462
Salaries, wages and benefits		17,307			1,018,267		681,606			—			1,717,180
Professional fees		—			107,115		133,868			—			240,983
Supplies		—			80,137		42,924			—			123,061
Rents and leases		—			34,443		47,786			—			82,229
Other operating expenses		—			243,478		131,955			—			375,433
Depreciation and amortization		—			81,105		82,939			—			164,044
Interest expense, net		76,138			92,538		18,418			—			187,094
Loss on impairment		—			27,217		27,169			—			54,386
Transaction-related expenses		—			21,156		5,908			—			27,064
Total expenses		93,445			1,705,456		1,172,573			—			2,971,474
Income (loss) before income taxes		(93,445	)		177,062		52,371			—			135,988
Equity in earnings of subsidiaries		174,216			—		—			(174,216	)		—
(Benefit from) provision for income taxes		(29,351	)		52,903		2,314			—			25,866
Net income (loss)		110,122			124,159		50,057			(174,216	)		110,122
Net income attributable to noncontrolling interests		—			—		(1,199	)		—			(1,199	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	110,122		$	124,159	$	48,858		$	(174,216	)	$	108,923
Other comprehensive income:
Foreign currency translation loss		—			—		69,811			—			69,811
Gain on derivative instruments		(19,008	)		—		—			—			(19,008	)
Pension liability adjustment, net		—			—		(3,310	)		—			(3,310	)
Other comprehensive income (loss)		(19,008	)		—		66,501			—			47,493
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	91,114		$	124,159	$	115,359		$	(174,216	)	$	156,416

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments		Total Consolidated Amounts
Revenue	$	—		$	1,788,757	$	1,223,685		$	—		3,012,442
Salaries, wages and benefits		22,001			965,419		671,928			—		1,659,348
Professional fees		—			98,441		128,984			—		227,425
Supplies		—			76,526		42,788			—		119,314
Rents and leases		—			33,101		47,181			—		80,282
Other operating expenses		—			225,446		129,052			—		354,498
Depreciation and amortization		—			74,341		84,491			—		158,832
Interest expense, net		65,588			92,983		26,839			—		185,410
Debt extinguishment costs		940			—		875			—		1,815
Legal settlements expense		—			22,076		—			—		22,076
Loss on impairment		—			—		337,889			—		337,889
Transaction-related expenses		—			29,720		4,787			—		34,507
Total expenses		88,529			1,618,053		1,474,814			—		3,181,396
(Loss) income before income taxes		(88,529	)		170,704		(251,129	)		—		(168,954	)
Equity in earnings of subsidiaries		(98,669	)		—		—			98,669		—
(Benefit from) provision for income taxes		(11,712	)		19,045		(801	)		—		6,532
Net (loss) income		(175,486	)		151,659		(250,328	)		98,669		(175,486	)
Net income attributable to noncontrolling interests		—			—		(264	)		—		(264	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(175,486	)	$	151,659	$	(250,592	)	$	98,669	$	(175,750	)
Other comprehensive income:
Foreign currency translation loss		—			—		(127,521	)		—		(127,521	)
Gain on derivative instruments		36,799			—		—			—		36,799
Pension liability adjustment, net		—			—		2,463			—		2,463
Other comprehensive income (loss)		36,799			—		(125,058	)		—		(88,259	)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$	(138,687	)	$	151,659	$	(375,650	)	$	98,669	$	(264,009	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,746,656		$	1,130,578		$	—		$	2,877,234
Provision for doubtful accounts		—			(35,636	)		(5,282	)		—			(40,918	)
Revenue		—			1,711,020			1,125,296			—			2,836,316
Salaries, wages and benefits		23,467			902,180			610,513			—			1,536,160
Professional fees		—			93,991			102,232			—			196,223
Supplies		—			75,248			39,191			—			114,439
Rents and leases		—			33,365			43,410			—			76,775
Other operating expenses		—			217,900			113,927			—			331,827
Depreciation and amortization		—			66,482			76,528			—			143,010
Interest expense, net		61,872			81,274			32,861			—			176,007
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			11,236			13,031			—			24,267
Total expenses		86,149			1,481,676			1,031,693			—			2,599,518
(Loss) income before income taxes		(86,149	)		229,344			93,603			—			236,798
Equity in earnings of subsidiaries		259,282			—			—			(259,282	)		—
(Benefit from) provision for income taxes		(26,456	)		69,882			(6,217	)		—			37,209
Net income (loss)		199,589			159,462			99,820			(259,282	)		199,589
Net loss attributable to noncontrolling interests		—			—			246			—			246
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	199,589		$	159,462		$	100,066		$	(259,282	)	$	199,835
Other comprehensive income:
Foreign currency translation gain		—			—			206,784			—			206,784
Loss on derivative instruments		(33,431	)		—			—			—			(33,431	)
Pension liability adjustment, net		—			—			2,099			—			2,099
Other comprehensive (loss) income		(33,431	)		—			208,883			—			175,452
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	166,158		$	159,462		$	308,949		$	(259,282	)	$	375,287

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net (loss) income	$	110,122		$	124,159		$	50,057		$	(174,216	)	$	110,122
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(174,216	)		—			—			174,216			—
Depreciation and amortization		—			81,105			82,939			—			164,044
Amortization of debt issuance costs		11,987			—			—			—			11,987
Equity-based compensation expense		17,307			—			—			—			17,307
Deferred income taxes		441			86			1,253			—			1,780
Loss on impairment		—			27,217			27,169			—			54,386
Other		1,814			2,100			121			—			4,035
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(13,380	)		(5,680	)		—			(19,060	)
Other current assets		—			776			(2,120	)		—			(1,344	)
Other assets		3,929			(2,501	)		2,428			(3,929	)		(73	)
Accounts payable and other accrued liabilities		—			(5,391	)		(15,963	)		—			(21,354	)
Accrued salaries and benefits		—			4,283			3,537			—			7,820
Other liabilities		—			15,110			(11,856	)		—			3,254
Net cash (used in) provided by continuing operating activities		(28,616	)		233,564			131,885			(3,929	)		332,904
Net cash used in discontinued operating activities		—			—			—			—			—
Net cash (used in) provided by operating activities		(28,616	)		233,564			131,885			(3,929	)		332,904
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(45,677	)		—			—			(45,677	)
Cash paid for capital expenditures		—			(188,161	)		(96,521	)		—			(284,682	)
Cash paid for real estate acquisitions		—			(7,618	)		—			—			(7,618	)
Settlement of foreign currency derivatives		105,008			—			—			—			105,008
Proceeds from sale of property and equipment		—			11,765			6,311			—			18,076
Other		—			13,752			—			—			13,752
Net cash used in investing activities		105,008			(215,939	)		(90,210	)		—			(201,141	)
Financing activities:
Borrowings on revolving credit facility		76,573			—			—			—			76,573
Principal payments on revolving credit facility		(76,573	)		—			—			—			(76,573	)
Principal payments on long-term debt		(52,984	)		—			(3,929	)		3,929			(52,984	)
Common stock withheld for minimum statutory taxes, net		(1,649	)		—			—			—			(1,649	)
Distributions to noncontrolling interests		—			—			(154	)		—			(154	)
Other		(2,375	)		(1,993	)		(2,472	)		—			(6,840	)
Cash provided by (used in) intercompany activity		(19,384	)		50,840			(31,456	)		—			—
Net cash provided by (used in) financing activities		(76,392	)		48,847			(38,011	)		3,929			(61,627	)
Effect of exchange rate changes on cash		—			—			3,546			—			3,546
Net decrease in cash and cash equivalents		—			66,472			7,210			—			73,682
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	98,943		$	25,249		$	—		$	124,192

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net (loss) income	$	(175,486	)	$	151,659		$	(250,328	)	$	98,669		$	(175,486	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		98,669			—			—			(98,669	)		—
Depreciation and amortization		—			74,341			84,491			—			158,832
Amortization of debt issuance costs		10,825			—			(369	)		—			10,456
Equity-based compensation expense		22,001			—			—			—			22,001
Deferred income taxes		529			(8,795	)		(1,448	)		—			(9,714	)
Debt extinguishment costs		940			—			875			—			1,815
Legal settlements expense		—			22,076			—			—			22,076
Loss on impairment		—			—			337,889			—			337,889
Other		6,981			5,457			(67	)		—			12,371
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(17,328	)		507			—			(16,821	)
Other current assets		—			14,881			(1,017	)		—			13,864
Other assets		4,596			118			2,644			(4,596	)		2,762
Accounts payable and other accrued liabilities		—			15,743			10,311			—			26,054
Accrued salaries and benefits		—			15,094			654			—			15,748
Other liabilities		—			3,014			(8,233	)		—			(5,219	)
Net cash (used in) provided by continuing operating activities		(30,945	)		276,260			175,909			(4,596	)		416,628
Net cash used in discontinued operating activities		—			(2,548	)		—			—			(2,548	)
Net cash (used in) provided by operating activities		(30,945	)		273,712			175,909			(4,596	)		414,080
Investing activities:
Cash paid for capital expenditures		—			(210,023	)		(131,439	)		—			(341,462	)
Cash paid for real estate acquisitions		—			(14,096	)		(4,287	)		—			(18,383	)
Proceeds from sale of property and equipment		—			5,168			3,080			—			8,248
Other		—			(9,367	)		—			—			(9,367	)
Net cash used in investing activities		—			(228,318	)		(132,646	)		—			(360,964	)
Financing activities:
Principal payments on long-term debt		(39,738	)		(169	)		(4,427	)		4,596			(39,738	)
Repayment of long-term debt		—			—			(21,920	)		—			(21,920	)
Common stock withheld for minimum statutory taxes, net		(3,407	)		—			—			—			(3,407	)
Other		(1,742	)		2,094			(2,617	)		—			(2,265	)
Cash provided by (used in) intercompany activity		75,832			(61,708	)		(14,124	)		—			—
Net cash provided by (used in) financing activities		30,945			(59,783	)		(43,088	)		4,596			(67,330	)
Effect of exchange rate changes on cash		—			—			(2,566	)		—			(2,566	)
Net decrease in cash and cash equivalents		—			(14,389	)		(2,391	)		—			(16,780	)
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	32,471		$	18,039		$	—		$	50,510

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	199,589		$	159,462		$	99,820		$	(259,282	)	$	199,589
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(259,282	)		—			—			259,282			—
Depreciation and amortization		—			66,482			76,528			—			143,010
Amortization of debt issuance costs		10,270			—			(415	)		—			9,855
Equity-based compensation expense		23,467			—			—			—			23,467
Deferred income taxes		1,236			28,882			1,254			—			31,372
Debt extinguishment costs		810			—			—			—			810
Other		4,189			2,498			4,725			—			11,412
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(21,791	)		(6,779	)		—			(28,570	)
Other current assets		—			(6,429	)		27,237			—			20,808
Other assets		24,549			(3,277	)		101			(24,549	)		(3,176	)
Accounts payable and other accrued liabilities		—			4,909			(15,022	)		—			(10,113	)
Accrued salaries and benefits		—			(3,974	)		(5,014	)		—			(8,988	)
Other liabilities		—			8,794			3,000			—			11,794
Net cash provided by (used in) continuing operating activities		4,828			235,556			185,435			(24,549	)		401,270
Net cash used in discontinued operating activities		—			(1,693	)		—			—			(1,693	)
Net cash provided by (used in) operating activities		4,828			233,863			185,435			(24,549	)		399,577
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			—			(18,191	)		—			(18,191	)
Cash paid for capital expenditures		—			(161,312	)		(112,865	)		—			(274,177	)
Cash paid for real estate acquisitions		—			(37,047	)		(4,010	)		—			(41,057	)
Proceeds from sale of property and equipment		—			2,415			2,837			—			5,252
Other		—			(10,359	)		2,006			—			(8,353	)
Net cash used in investing activities		—			(206,303	)		(130,223	)		—			(336,526	)
Financing activities:
Principal payments on long-term debt		(57,050	)		(14,250	)		(10,554	)		24,549			(57,305	)
Common stock withheld for minimum statutory taxes, net		(3,455	)		—			—			—			(3,455	)
Other		(539	)		1,225			—			—			686
Cash provided by (used in) intercompany activity		56,216			16,644			(72,860	)		—			—
Net cash (used in) provided by financing activities		(4,828	)		3,619			(83,414	)		24,549			(60,074	)
Effect of exchange rate changes on cash		—			—			7,250			—			7,250
Net increase (decrease) in cash and cash equivalents		—			31,179			(20,952	)		—			10,227
Cash and cash equivalents at beginning of the period		—			15,681			41,382			—			57,063
Cash and cash equivalents at end of the period	$	—		$	46,860		$	20,430		$	—		$	67,290

Property and Equipment

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Property and Equipment

6. Property and Equipment

Property and equipment consisted of the following at December 31, 2019 and 2018 (in thousands):

	December 31,
	2019			2018
Land	$	448,716		$	430,771
Building and improvements		2,746,111			2,423,594
Equipment		516,769			444,538
Construction in progress		254,213			294,848
		3,965,809			3,593,751
Less: accumulated depreciation		(741,775	)		(485,985	)
Property and equipment, net	$	3,224,034		$	3,107,766

During the first quarter of 2019, the Company closed a 168-bed residential treatment center in Albuquerque, New Mexico. During the third quarter of 2019, the Company closed a 108-bed residential treatment center in Butte, Montana. During the fourth quarter of 2019, the Company determined the carrying amounts of these properties may not be recoverable, and a loss on impairment of $27.2 million was recorded related to these closed U.S. Facilities. Additionally, the Company recorded a loss on impairment of $27.2 million in the fourth quarter of 2019 related to certain closed U.K. Facilities. The closed properties are being actively marketed and are included in assets held for sale within other assets on the consolidated balance sheets at December 31, 2019. The Company has recorded assets held for sale of $31.1 million and $17.0 million at December 31, 2019 and December 31, 2018, respectively.

Property and Equipment - Additional information (Detail) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2019 USD ($)	Sep. 30, 2019 Bed	Mar. 31, 2019 Bed	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Property Plant And Equipment [Line Items]
Loss on impairment	$ 54,400			$ 337,900	$ 54,386	$ 337,889
Assets held for sale	31,100			$ 17,000	$ 31,100	$ 17,000
U.S. Facilities [Member]
Property Plant And Equipment [Line Items]
Loss on impairment	27,200
U.K. Facilities [Member]
Property Plant And Equipment [Line Items]
Loss on impairment	$ 27,200
Residential Treatment Centers [Member] \| Albuquerque, New Mexico [Member]
Property Plant And Equipment [Line Items]
Number of beds in facilities closed \| Bed			168
Residential Treatment Centers [Member] \| Butte, Montana [Member]
Property Plant And Equipment [Line Items]
Number of beds in facilities closed \| Bed		108

Equity-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000
Equity incentive plan available for future grant	2,903,059
Annual increments in employee grants	25.00%
Stock options, contractual term	10 years
Equity-based compensation expense	$ 17,307,000	$ 22,001,000	$ 23,467,000
Vesting targets	(6,400,000)	(5,500,000)	(5,700,000)
Unrecognized compensation expense related to unvested options	$ 34,300,000
Vesting period	1 year 2 months 12 days
Warrant outstanding	$ 0
Deferred income tax benefit	1,780,000	(9,714,000)	$ 31,372,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 4,200,000	$ 7,000,000.0
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Number of shares issuable at the end of the vesting period, percentage	0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of shares issuable at the end of the vesting period, percentage	200.00%

Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal	$ 18,954	$ 13,961	$ 3,325
State	3,440	1,113	680
Foreign	1,692	1,172	1,832
Total current	24,086	16,246	5,837
Deferred:
Federal	(1,573)	(7,176)	27,179
State	2,509	(10)	4,408
Foreign	844	(2,528)	(215)
Total deferred provision	1,780	(9,714)	31,372
Provision for income taxes	$ 25,866	$ 6,532	$ 37,209

Long-Term Debt (Debt Issuance Costs) - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt issuance costs	$ 29.0	$ 37.8
Accumulated amortization	46.2	36.5
Amortization expenses reported as interest expense	$ 9.7	$ 9.0	$ 8.6

Employee Benefit Plans - Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member]	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	1.40%	1.30%
Foreign Government Debt Securities [Member] \| United Kingdom [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	16.20%	15.00%
Annuity Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	35.10%	38.60%
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	28.80%	25.40%
Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	12.50%	15.80%
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Weighted-average asset allocation	6.00%	3.90%

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Dec. 31, 2019	Dec. 31, 2018	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Summary of Significant Accounting Policies - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued expenses	$ 50,614	$ 44,938
Accrued interest	33,323	32,838
Unearned income	38,475	32,154
Finance lease liabilities	6,819
Insurance liability – current portion	4,731	4,956
Accrued property taxes	4,755	4,136
Income taxes payable		3,041
Accrued legal settlements		22,076
Other	2,443	7,087
Other accrued liabilities	$ 141,160	$ 151,226

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Dec. 31, 2019
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	6 years 10 months 24 days
Operating lease, weighted average remaining term (years)	19 years 4 months 24 days
Finance lease, weighted average discount rate percent	6.40%
Operating lease, weighted average discount rate percent	6.30%

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. Commitments and Contingencies

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. At this time, we are not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated and ordered stayed pending a ruling on the motion to dismiss that was filed in the St. Clair County v. Acadia Healthcare

case described above. At this time, we are not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

During the second quarter of 2019, the Company reached a settlement with the U.S. Attorney’s Office for the Southern District of West Virginia relating to the manner in which seven of our comprehensive treatment centers in West Virginia had historically billed lab claims to the West Virginia Medicaid Program. The Company paid the government $17.0 million during the three months ended June 30, 2019 and entered into a corporate integrity agreement with the Office of Inspector General imposing customary compliance obligations on us and our subsidiary, CRC Health.

In the fall of 2017, the Office of Inspector General issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the Office of Inspector General issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Segment Information (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Reconciliation of Segment EBITDA to Income before Income Taxes

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Year Ended December 31,
	2019			2018			2017
Revenue:
U.S. Facilities	$	2,008,381		$	1,904,695		$	1,809,844
U.K. Facilities		1,099,081			1,107,747			1,026,472
Corporate and Other		—			—			—
	$	3,107,462		$	3,012,442		$	2,836,316
Segment EBITDA (1) :
U.S. Facilities	$	503,358		$	488,207		$	475,260
U.K. Facilities		166,693			185,755			198,566
Corporate and Other		(84,168	)		(80,386	)		(69,467	)
	$	585,883		$	593,576		$	604,359

	Year Ended December 31,
	2019			2018			2017
Segment EBITDA(1)	$	585,883		$	593,576		$	604,359
Plus (less):
Equity-based compensation expense		(17,307	)		(22,001	)		(23,467	)
Debt extinguishment costs		—			(1,815	)		(810	)
Legal settlements expense		—			(22,076	)		—
Loss on impairment		(54,386	)		(337,889	)		—
Transaction-related expenses		(27,064	)		(34,507	)		(24,267	)
Interest expense, net		(187,094	)		(185,410	)		(176,007	)
Depreciation and amortization		(164,044	)		(158,832	)		(143,010	)
Income (loss) before income taxes	$	135,988		$	(168,954	)	$	236,798

Summary of Assets by Operating Segment

	December 31,
	2019		2018
Assets (2) :
U.S. Facilities	$	4,037,968	$	3,779,040
U.K. Facilities		2,610,357		2,175,809
Corporate and Other		230,817		217,655
	$	6,879,142	$	6,172,504

(1)

Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, legal settlements expense, loss on impairment, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $50.9 million at December 31, 2019. Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $44.9 million at December 31, 2018.

Goodwill [Member]

Summary of Assets by Operating Segment

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2018
Goodwill	$	2,042,592	$	708,582		$	—	$	2,751,174
Accumulated impairment loss		—		—			—		—
Net goodwill at January 1, 2018		2,042,592		708,582			—		2,751,174
Loss on impairment		—		(325,875	)		—		(325,875	)
Increase from contribution of redeemable noncontrolling interests		2,245		—			—		2,245
Foreign currency translation loss		—		(31,894	)		—		(31,894	)
Prior year purchase price adjustments		—		762			—		762
Balance at December 31, 2018
Goodwill		2,044,837		677,450			—		2,722,287
Accumulated impairment loss		—		(325,875	)		—		(325,875	)
Net goodwill at December 31, 2018		2,044,837		351,575			—		2,396,412
Increase from contribution of redeemable noncontrolling interests		3,300		—			—		3,300
Increase from 2019 acquisitions		36,967		—			—		36,967
Foreign currency translation gain		—		12,452			—		12,452
Balance at December 31, 2019
Goodwill		2,085,104		689,902			—		2,775,006
Accumulated impairment loss		—		(325,875	)		—		(325,875	)
Net goodwill at December 31, 2019	$	2,085,104	$	364,027		$	—	$	2,449,131

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,231	$ 3,247
Intangible assets not subject to amortization, Gross Carrying Amount	90,357	88,990
Total	93,588	92,237
Intangible assets subject to amortization, Accumulated Amortization	(3,231)	(3,247)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,231)	(3,247)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,455	12,343
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	60,831	60,109
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	17,071	16,538
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,147
Intangible assets subject to amortization, Accumulated Amortization	$ (1,131)	$ (1,147)

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

14. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, other long-term debt and derivative instruments at December 31, 2019 and 2018 were as follows (in thousands):

	Carrying Amount					Fair Value
	December 31,					December 31,
	2019			2018		2019			2018
Amended and Restated Senior Credit Facility	$	1,668,062		$	1,715,338	$	1,668,062		$	1,715,338
6.125% Senior Notes due 2021	$	149,254		$	148,657	$	149,441		$	147,542
5.125% Senior Notes due 2022	$	297,761		$	296,946	$	299,994		$	283,583
5.625% Senior Notes due 2023	$	644,771		$	643,289	$	655,249		$	609,516
6.500% Senior Notes due 2024	$	384,430		$	383,304	$	398,366		$	369,888
Other long-term debt	$	4,821		$	5,953	$	4,821		$	5,953
Derivative instrument (liabilities) assets	$	(68,915	)	$	60,524	$	(68,915	)	$	60,524

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) Facility Bed State	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Accounting Policies [Abstract]
Number of facilities \| Facility	585
Number of beds \| Bed	18,200
Number of operating states \| State	40
General and administrative expenses \| $	$ 90.4	$ 86.6	$ 76.4

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	$ 3,107,462	$ 3,012,442	$ 2,836,316
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									2,008,381	1,904,695	1,809,844
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									912,097	814,124	757,211
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									788,232	761,017	725,151
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue									286,959	293,053	284,637
U.S. Facilities [Member] \| Outpatient Community-Based Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									$ 21,093	$ 36,501	$ 42,845

Income Taxes - Unrecognized Income Tax Benefits Net of Federal Benefit (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Balance at January 1	$ 713	$ 6,104
Additions based on tax positions related to the current year	3,001	52
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities	(1,273)	(5,443)
Balance at December 31	$ 2,441	$ 713

Revenue - Schedule of U.S. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 3,107,462	$ 3,012,442	$ 2,877,234
Provision for doubtful accounts											(40,918)
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	3,107,462	3,012,442	2,836,316
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									2,008,381	1,904,695	1,850,556
Provision for doubtful accounts											(40,712)
Revenue									$ 2,008,381	$ 1,904,695	$ 1,809,844
Revenue before provision for doubtful accounts, Percentage									100.00%	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 565,350	$ 573,089	$ 569,242
Revenue before provision for doubtful accounts, Percentage									28.20%	30.10%	30.80%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 294,691	$ 280,340	$ 281,270
Revenue before provision for doubtful accounts, Percentage									14.70%	14.70%	15.20%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 1,007,102	$ 893,644	$ 796,375
Revenue before provision for doubtful accounts, Percentage									50.10%	46.90%	43.00%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 118,716	$ 134,054	$ 169,727
Revenue before provision for doubtful accounts, Percentage									5.90%	7.10%	9.20%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 22,522	$ 23,568	$ 33,942
Revenue before provision for doubtful accounts, Percentage									1.10%	1.20%	1.80%

Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Components Of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2017	$	(584,081	)	$	40,598		$	(6,087	)	$	(549,570	)
Foreign currency translation gain (loss)		207,341			—			(557	)		206,784
Loss on derivative instruments, net of tax of $(22.9) million		—			(33,431	)		—			(33,431	)
Pension liability adjustment, net of tax of $0.4 million		—			—			2,099			2,099
Balance at December 31, 2017		(376,740	)		7,167			(4,545	)		(374,118	)
Foreign currency translation (loss) gain		(127,788	)		—			267			(127,521	)
Gain on derivative instruments, net of tax of $12.7 million		—			36,799			—			36,799
Pension liability adjustment, net of tax of $0.3 million		—			—			2,463			2,463
Balance at December 31, 2018		(504,528	)		43,966			(1,815	)		(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019	$	(434,633	)	$	24,958		$	(5,209	)	$	(414,884	)

Acquisitions - Additional Information (Detail) $ in Millions	Apr. 01, 2019 USD ($) Bed	Feb. 15, 2019 USD ($) Bed Center	Nov. 13, 2017 USD ($) Bed	Dec. 31, 2019 Bed
Business Acquisition [Line Items]
Number of beds \| Bed				18,200
Bradford [Member]
Business Acquisition [Line Items]
Number of beds \| Bed	46
Business acquisition cash consideration \| $	$ 4.5
Whittier Pavilion [Member] \| Massachusetts [Member]
Business Acquisition [Line Items]
Number of beds \| Bed		71
Business acquisition cash consideration \| $		$ 17.9
Mission Treatment [Member] \| California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration \| $		$ 22.5
Number of comprehensive treatment centers operates \| Center		9
Aspire [Member]
Business Acquisition [Line Items]
Number of beds \| Bed			36
Business acquisition cash consideration \| $			$ 21.3

Leases - Schedule of Supplemental Data (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 62,122
Operating cash flows for finance leases	3,991
Financing cash flows for finance leases	3,270
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	21,809
Finance leases	$ 3,234

Segment Information - Summary of Reconciliation of Segment EBITDA to Income before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	$ 3,107,462	$ 3,012,442	$ 2,836,316
Segment EBITDA									585,883	593,576	604,359
Equity-based compensation expense									(17,307)	(22,001)	(23,467)
Debt extinguishment costs										(1,815)	(810)
Legal settlements expense					(22,100)					(22,076)
Loss on impairment	(54,400)				(337,900)				(54,386)	(337,889)
Transaction-related expenses									(27,064)	(34,507)	(24,267)
Interest expense, net									(187,094)	(185,410)	(176,007)
Depreciation and amortization									(164,044)	(158,832)	(143,010)
Income (loss) before income taxes	(10,248)	$ 49,560	$ 59,805	$ 36,871	$ (341,336)	$ 55,036	$ 69,258	$ 48,088	135,988	(168,954)	236,798
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue									2,008,381	1,904,695	1,809,844
Loss on impairment	(27,200)
U.S. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									2,008,381	1,904,695	1,809,844
Segment EBITDA									503,358	488,207	475,260
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue									1,099,081	1,107,747	1,026,472
Loss on impairment	$ (27,200)
U.K. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue									1,099,081	1,107,747	1,026,472
Segment EBITDA									166,693	185,755	198,566
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Segment EBITDA									$ (84,168)	$ (80,386)	$ (69,467)

Long-Term Debt

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Long-Term Debt

9. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31, 2019			December 31, 2018
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	346,750		$	365,750
Senior Secured Term B Loans		1,338,928			1,372,912
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		4,821			5,953
Less: unamortized debt issuance costs, discount and premium		(31,400	)		(41,128	)
		3,149,099			3,193,487
Less: current portion		(43,679	)		(34,112	)
Long-term debt	$	3,105,420		$	3,159,375

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”).

The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC.

On May 10, 2017, the Company entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the Term Loan B facility Tranche B-1 (the “Tranche B-1 Facility”) and the Term Loan B facility Tranche B-2 (the “Tranche B-2 Facility”) from 3.00% to 2.75% in the case of Eurodollar Rate loans and from 2.00% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, the Company recorded a debt extinguishment charge of $0.8 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.

On March 22, 2018, the Company entered into a Second Repricing Facilities Amendment (the “Second Repricing Facilities Amendment”) to the Amended and Restated Credit Agreement. The Second Repricing Facilities Amendment (i) replaced the Tranche B-1 Facility and the Tranche B-2 Facility with a new Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) and a new Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”), respectively, and (ii) reduced the Applicable Rate from 2.75% to 2.50% in the case of Eurodollar Rate loans and reduced the Applicable Rate from 1.75% to 1.50% in the case of Base Rate Loans.

On March 29, 2018, the Company entered into a Third Repricing Facilities Amendment to the Amended and Restated Credit Agreement (the “Third Repricing Facilities Amendment”, and together with the Second Repricing Facilities Amendment, the “Repricing Facilities Amendments”). The Third Repricing Facilities Amendment replaced the existing revolving credit facility and Term Loan A facility (“TLA Facility”) with a new revolving credit facility and TLA Facility, respectively. The Company’s line of credit on its revolving credit facility remains at $500.0 million and the Third Repricing Facility Amendment reduced the size of the TLA Facility from $400.0 million to $380.0 million to reflect the then current outstanding principal. The Third Repricing Facilities Amendment reduced the Applicable Rate by 25 basis points for the revolving credit facility and the TLA Facility by amending the definition of “Applicable Rate.”

In connection with the Repricing Facilities Amendments, the Company recorded a debt extinguishment charge of $0.9 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.

On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants.

On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased our permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants.

The Company had $485.1 million of availability under the revolving line of credit and had standby letters of credit outstanding of $14.9 million related to security for the payment of claims required by its workers’ compensation insurance program at December 31, 2019. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $7.1 million for March 31, 2020 to December 31, 2020, and $9.5 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Tranche B-3 Facility in equal quarterly installments of $1.2 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-3 Facility due on February 11, 2022. The Company is required to repay the Tranche B-4 Facility in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility due on February 16, 2023. On December 29, 2017, the Company made an additional payment of $22.5 million, including $7.7 million on the Tranche B-1 Facility and $14.8 million on the Tranche B-2 Facility. On April 17, 2018, the Company made an additional payment of $15.0 million, including $5.1 million on the Tranche B-3 Facility and $9.9 million on the Tranche B-4 Facility. On November 15, 2019, the Company made an additional payment of $20.0 million, including $7.0 million on the Tranche B-3 Facility and $13.0 million on the Tranche B-4 Facility.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s

Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $50.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.5% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.5% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2019. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. At December 31, 2019, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.5%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of December 31, 2019, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of The Pavilion at HealthPark, LLC (“Park Royal”), the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively.

On December 1, 2018, the Company exercised the option to redeem in whole the 9.0% and 9.5% Revenue Bonds at a redemption price equal to the sum of 104% of the principal amount of the 9.0% and 9.5% Revenue Bonds plus accrued and unpaid interest. In connection with the redemption of the 9.0% and 9.5% Revenue Bonds, the Company recorded a debt extinguishment charge of $0.9 million, which was recorded in debt extinguishment costs in the consolidated statements of operations.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 2019 were $29.0 million, net of accumulated amortization of $46.2 million. Debt issuance costs at December 31, 2018 were $37.8 million, net of accumulated amortization of $36.5 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $9.7 million, $9.0 million and $8.6 million, respectively, for the years ended December 31, 2019, 2018 and 2017.

Other

The aggregate maturities of long-term debt at December 31, 2019 were as follows (in thousands):

2020	$	43,675
2021		483,501
2022		757,855
2023		1,505,468
2024		390,000
Thereafter		—
Total	$	3,180,499

Long-Term Debt (Other) - Summary of Aggregate Maturities of Long-Term Debt (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Debt Disclosure [Abstract]
2020	$ 43,675
2021	483,501
2022	757,855
2023	1,505,468
2024	390,000
Total	$ 3,180,499

Accumulated Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,333,307	$ 2,572,871	$ 2,167,724
Foreign currency translation (loss) gain	69,811	(127,521)	206,784
(Loss) gain on derivative instruments, net of tax of $(3.6) million, $12.7 million and $(22.9), respectively	(19,008)	36,799	(33,431)
Pension liability adjustment, net of tax of $(0.6) million, $0.3 million and $0.4 million, respectively	(3,310)	2,463	2,099
Balance	2,505,381	2,333,307	2,572,871
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(504,528)	(376,740)	(584,081)
Foreign currency translation (loss) gain	69,895	(127,788)	207,341
Balance	(434,633)	(504,528)	(376,740)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	43,966	7,167	40,598
(Loss) gain on derivative instruments, net of tax of $(3.6) million, $12.7 million and $(22.9), respectively	(19,008)	36,799	(33,431)
Balance	24,958	43,966	7,167
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,815)	(4,545)	(6,087)
Foreign currency translation (loss) gain	(84)	267	(557)
Pension liability adjustment, net of tax of $(0.6) million, $0.3 million and $0.4 million, respectively	(3,310)	2,463	2,099
Balance	(5,209)	(1,815)	(4,545)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(462,377)	(374,118)	(549,570)
Balance	$ (414,884)	$ (462,377)	$ (374,118)

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Employee benefit plan, Accumulated other comprehensive income (loss) , Net	$ (5,200)	$ (1,800)	$ (4,500)
Defined Contribution Plan [Member] \| 401(k) [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution expense	4,100	3,500	$ 200
Pension Plan [Member] \| Partnership in Care Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension liability under defined benefit pension plan	66,468	57,993
Pension Plan [Member] \| Partnership in Care Benefits Plan [Member] \| Other Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Pension liability under defined benefit pension plan	$ 4,300	$ 3,500

Quarterly Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2019 and 2018.

	Quarter Ended
	March 31,			June 30,		September 30,		December 31,
	(In thousands except per share amounts)
2019:
Revenue	$	760,617		$	789,362	$	777,251	$	780,232
Income before income taxes	$	36,871		$	59,805	$	49,560	$	(10,248	)
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	29,471		$	48,140	$	42,566	$	(11,254	)	⁽¹⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.34		$	0.55	$	0.49	$	(0.13	)	⁽¹⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.34		$	0.55	$	0.48	$	(0.13	)	⁽¹⁾
2018:
Revenue	$	742,241		$	765,738	$	760,916	$	743,547
Income (loss) before income taxes	$	48,088		$	69,258	$	55,036	$	(341,336	)
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	50,819	⁽²⁾	$	58,836	$	46,232	$	(331,637	)	⁽³⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.58	⁽²⁾	$	0.67	$	0.53	$	(3.80	)	⁽³⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.58	⁽²⁾	$	0.67	$	0.53	$	(3.80	)	⁽³⁾

(1)	Includes a loss on impairment of $54.4 million.

(2)	Includes tax benefits of $10.5 million pursuant to a change in the Company’s provisional amounts recorded at December 31, 2017 related to the enactment of the Tax Act.

(3)	Includes loss on impairment of $337.9 million and legal settlements expense of $22.1 million.

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 17.59	$ 13.67	$ 14.39
Risk-free interest rate	2.40%	2.20%	2.00%
Expected volatility	38.00%	37.00%	33.00%
Expected life (in years)	5 years	5 years 1 month 6 days	5 years 6 months

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Examination [Line Items]
Valuation allowance against deferred tax assets	$ 28,648	$ 24,079
Domestic net operating loss carryforward	0	0
Foreign net operating loss carryforwards	70,000	81,000
State net operating loss carry forwards	$ 220,800	236,000
Operating loss carryforwards expiration start year	2020
Operating loss carryforwards expiration end year	2038
Expiration of State tax credits	2029
State tax credits	$ 800
Income taxes receivable	5,579	2,380
Income tax payable included in other accrued liabilities		3,041
Unrecognized tax benefits	2,441	713	$ 6,104
Interest and penalties related to unrecognized tax benefits	600	$ 100
Unrecognized tax benefits would impact effective tax rate	$ 1,000
Exemption of tax credit	1.30%	(1.00%)
U.S. federal statutory rate on income before income taxes	21.00%	21.00%	35.00%
Deferred tax balance		$ 20,600
Transition tax on certain repatriated earnings of foreign subsidiaries payable period	8 years
One-time transition tax liability, foreign earnings		0
Reduction to deferred tax balance		400	$ 20,200
Provisional amount of transition tax liability, foreign subsidiaries		0
Foreign dividends		10,900
Foreign earnings tax liability	$ 0
Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	50.00%
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2015
Period of examination by internal revenue service maximum	2018
Foreign Tax Authority [Member] \| U.K Tax Authorities [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2014
Period of examination by internal revenue service maximum	2018
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service minimum	2013
Period of examination by internal revenue service maximum	2018
Payroll [Member] \| Maximum [Member]
Income Tax Examination [Line Items]
Exemption of tax credit	15.00%
Earliest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2016
Latest Tax Year [Member] \| Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Period of examination by internal revenue service	2018
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	$ 3,100	$ 900

Earnings Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Earnings Per Share

4. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019, 2018 and 2017 (in thousands, except per share amounts):

	Year Ended December 31,
	2019		2018			2017
Numerator:
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	108,923	$	(175,750	)	$	199,835
Denominator:
Weighted average shares outstanding for basic earnings per share		87,612		87,288			86,948
Effects of dilutive instruments		204		—			112
Shares used in computing diluted earnings per common share		87,816		87,288			87,060
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	1.24	$	(2.01	)	$	2.30
Diluted	$	1.24	$	(2.01	)	$	2.30

Approximately 2.2 million, 1.9 million and 1.4 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2019, 2018 and 2017, respectively, because their effect would have been anti-dilutive. For the year ended December 31, 2018, approximately 0.1 million of the outstanding restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards have been excluded from the calculation of diluted earnings per share because the net loss for the year ended December 31, 2018 causes such securities to be anti-dilutive.

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	805,057	809,868	844,419
Granted, Number of Shares	700,937	480,137	404,224
Cancelled, Number of Shares	(389,684)	(88,989)	(145,981)
Vested, Number of Shares	(311,174)	(395,959)	(292,794)
Unvested, Number of Shares/Units, Ending balance	805,136	805,057	809,868
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 42.40	$ 50.19	$ 55.76
Granted, Weighted Average Grant-Date Fair Value	28.77	36.84	42.38
Cancelled, Weighted Average Grant-Date Fair Value	33.50	47.57	55.03
Vested, Weighted Average Grant-Date Fair Value	44.23	50.41	53.07
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 34.14	$ 42.40	$ 50.19

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands		12 Months Ended
	Dec. 01, 2018	Dec. 31, 2018	Dec. 31, 2017	Nov. 11, 2012
Debt Instrument [Line Items]
Debt extinguishment charge		$ (1,815)	$ (810)
9.0% and 9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 23,000
9.0% and 9.5% Revenue Bonds [Member] \| Fair Value [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%
Debt instrument, redemption price percentage of principal amount	104.00%
Debt instrument, Redemption date	Dec. 01, 2018
Debt extinguishment charge	$ (900)
9.0% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 7,500
Debt instrument interest rate				9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%
Debt instrument, redemption price percentage of principal amount	104.00%
Debt instrument, Redemption date	Dec. 01, 2018
Debt extinguishment charge	$ (900)
9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds				$ 15,500
Debt instrument interest rate				9.50%

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

12. Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2019			2018			2017
Current:
Federal	$	18,954		$	13,961		$	3,325
State		3,440			1,113			680
Foreign		1,692			1,172			1,832
Total current		24,086			16,246			5,837
Deferred:
Federal		(1,573	)		(7,176	)		27,179
State		2,509			(10	)		4,408
Foreign		844			(2,528	)		(215	)
Total deferred provision		1,780			(9,714	)		31,372
Provision for income taxes	$	25,866		$	6,532		$	37,209

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2019			2018			2017
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		35.0	%
Impact of foreign operations		(15.3	)		9.5			(14.1	)
Impacts of SAB 118		—			6.7			—
Effects of statutory rate change		—			—			(8.5	)
State income taxes, net of federal tax effect		3.3			(1.4	)		2.1
Permanent differences		2.4			(4.1	)		1.8
Goodwill impairment		—			(36.6	)		—
Change in valuation allowance		2.9			(1.4	)		1.6
Unrecognized tax benefit release		0.3			3.1			(0.8	)
Interest disallowance		4.2			(2.2	)		—
Federal tax credits		(1.3	)		1.0			—
Other		1.5			0.5			(1.4	)
Effective income tax rate		19.0	%		(3.9	)%		15.7	%

The domestic and foreign components of income (loss) before income taxes are as follows (in thousands):

	Year Ended December 31,
	2019		2018			2017
Foreign	$	61,921	$	(228,350	)	$	120,905
Domestic		74,067		59,396			115,893
Total	$	135,988	$	(168,954	)	$	236,798

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 2019 and December 31, 2018 were as follows (in thousands):

	December 31,
	2019			2018
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	25,118		$	27,294
Bad debt allowance		996			898
Accrued compensation and severance		14,645			15,229
Pension reserves		724			595
Insurance reserves		16,485			13,994
Leases		3,436			5,374
Accrued expenses		1,496			4,231
Interest carryforwards		59,413			32,272
Lease liabilities		98,419			—
Other assets		2,562			2,284
Total gross deferred tax assets		223,294			102,171
Less: valuation allowance		(28,648	)		(24,079	)
Deferred tax assets		194,646			78,092
Deferred tax liabilities:
Fixed asset basis difference		(43,992	)		(48,698	)
Prepaid items		(2,163	)		(1,728	)
Intangible assets		(104,542	)		(87,628	)
Lease right-of-use assets		(99,677	)		—
Other liabilities		(12,793	)		(16,942	)
Total deferred tax liabilities		(263,167	)		(154,996	)
Total net deferred tax liability	$	(68,521	)	$	(76,904	)

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. At December 31, 2019 and 2018, the Company carried a valuation allowance against deferred tax assets of $28.6 million and $24.1 million, respectively.

As of December 31, 2019 and 2018, the Company had no domestic net operating loss carryforwards. The foreign net operating loss carryforwards at December 31, 2019 and 2018 are approximately $70.0 million and $81.0 million, respectively, and have no expiration.

The Company has state net operating loss carryforwards at December 31, 2019 and 2018 of approximately $220.8 million and $236.0 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 2020 to 2038. In addition, the Company has certain state tax credits of $0.8 million which will begin to expire in 2029 if not utilized.

Income taxes receivable was $5.6 million and $2.4 million at December 31, 2019 and 2018, respectively, and was included in other current assets in the consolidated balance sheets. Income taxes payable of $3.0 million at December 31, 2018 was included in other accrued liabilities in the consolidated balance sheets.

The Company has recorded income taxes payable related to unrecognized tax benefits of $3.1 million and $0.9 million at December 31, 2019 and 2018, respectively, in other liabilities in the consolidated balance sheets. A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands):

	2019			2018
Balance at January 1	$	713		$	6,104
Additions based on tax positions related to the current year		3,001			52
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(1,273	)		(5,443	)
Balance at December 31	$	2,441		$	713

The Company recognizes interest and penalties related to unrecognized tax benefits in its consolidated balance sheets. At December 31, 2019 and 2018, the cumulative amounts recognized were $0.6 million and $0.1 million, respectively. Unrecognized tax benefits of $1.0 million would affect the effective rate if recognized. It is possible the amount of unrecognized tax benefit could change in the next twelve months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, management does not anticipate the change will have a material impact on the Company’s consolidated financial statements.

The Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant taxing authorities. The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2016 through 2018. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. The Company is subject to inquiry, for calendar years 2014 through 2018, by foreign taxing authorities within the U. K. While no other foreign jurisdictions are presently under examination, the Company may be subject to examination for calendar years 2015 through 2018. Generally, for state tax purposes, the Company’s 2013 through 2018 tax years remain open for examination by the tax authorities. At the date of this report there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

One of the Company’s Puerto Rico subsidiaries was granted a tax exemption for which a tax credit of up to 15% of eligible payroll expenses is available to offset up to 50% of the income taxes attributed to that entity.

U.S. Tax Reform

On December 22, 2017, Public Law 115-97, informally referred to as The Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law. The Tax Act provided for significant changes to the U.S. tax code that has impacted businesses. Effective January 1, 2018, the Tax Act reduced the U.S. federal tax rate for corporations from 35% to 21%, for U.S. taxable income. The Tax Act included other changes, including, but not limited to, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, a new provision designed to tax global intangible low-taxed income, a limitation of the deduction for net operating losses, elimination of net operating loss carrybacks, immediate deductions for depreciation expense for certain qualified property, additional limitations on the deductibility of executive compensation and limitations on the deductibility of interest.

ASC 740 “Income Taxes” (“ASC 740”) requires the Company to recognize the effect of tax law changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin 118 (“SAB 118”) which allowed the Company to record provisional amounts during a measurement period similar to the measurement period used when accounting for business combinations.

The Tax Act required a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21% and a one-time transition tax on certain repatriated earnings of foreign subsidiaries that is payable over eight years. At December 31, 2018, the Company has completed its accounting for the tax effects of the enactment of the Tax Act. At December 31, 2018, the Company has recorded a reduction in net deferred taxes of $20.6 million related to the remeasurement of its deferred tax balance. In addition, the Company has recorded a one-time transition tax liability in relation to its foreign subsidiaries of $0.0 million at December 31, 2018. The Company continues to assess the impact of the Tax Act on its business.

Deferred Tax Assets and Liabilities

The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. As a result of the reduction in the corporate income tax rate, the Company was required to revalue its net deferred tax assets and liabilities to account for the future impact of lower corporate tax rates on this deferred amount and record any change in the value of such asset or liability as a one-time non-cash charge or benefit on its income statement. The Company recorded a reduction in net deferred taxes of $20.2 million as of December 31, 2017 and an additional reduction of $0.4 million as of December 31, 2018 for a total reduction in net deferred taxes of $20.6 million related to the remeasurement of its deferred tax balance.

U.S. Tax on Foreign Earnings

The one-time transition tax is based on total post-1986 earnings and profits that the Company previously deferred from U.S. income taxes. At December 31, 2018, the Company has completed the earnings and profits analysis for its foreign subsidiaries to calculate the effects of the one-time transition tax and has recorded a one-time transition tax liability amount of $0.0 million. As part of the analysis of the Tax Act, the Company made an adjustment regarding the treatment of foreign dividends of $10.9 million during the twelve months ended December 31, 2018. The change in the provisional estimate recorded at December 31, 2017 was recognized under the law that existed prior to December 22, 2017.

The Company has continued to analyze the impacts for Global Intangible Low-Taxed Income (“GILTI”), Foreign-Derived Intangible Income, the Base Erosion and Anti-Abuse Tax and any remaining impacts of the foreign income provisions of the Tax Act. At December 31, 2019, the Company has recorded a tax liability amount of $0.0 million relating to such items.

The Tax Act subjects a U.S. shareholder to tax on GILTI earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, “Accounting for Global Intangible Low-Taxed Income”, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to account for GILTI in the year the tax is incurred.

Income Taxes - Effective Income Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Income Tax Rate (Detail)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory rate on income before income taxes	21.00%	21.00%	35.00%
Impact of foreign operations	(15.30%)	9.50%	(14.10%)
Impacts of SAB 118		6.7
Effects of statutory rate change			(8.50%)
State income taxes, net of federal tax effect	3.30%	(1.40%)	2.10%
Permanent differences	2.40%	(4.10%)	1.80%
Goodwill impairment		(36.60%)
Change in valuation allowance	2.90%	(1.40%)	1.60%
Unrecognized tax benefit release	0.30%	3.10%	(0.80%)
Interest disallowance	4.20%	(2.20%)
Federal tax credits	(1.30%)	1.00%
Other	1.50%	0.50%	(1.40%)
Effective income tax rate	19.00%	(3.90%)	15.70%

Acquisitions

12 Months Ended

Dec. 31, 2019

Business Combinations [Abstract]

Acquisitions

5. Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center (“Bradford”), a specialty treatment facility with 46 beds located in Millerton, Pennsylvania, for cash consideration of approximately $4.5 million.

On February 15, 2019, the Company completed the acquisition of Whittier Pavilion (“Whittier”), an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment (“Mission Treatment”) for cash consideration of approximately $22.5 million and a working capital settlement. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma.

On November 13, 2017, the Company completed the acquisition of Aspire Scotland, an education facility with 36 beds located in Scotland, for cash consideration of approximately $21.3 million.

Transaction-related expenses

	Year Ended December 31,
	2019		2018		2017
Termination, restructuring and strategic review costs	$	18,233	$	16,785	$	19,469
Management transition costs		5,529		14,033		—
Legal, accounting and other acquisition-related costs		3,302		3,689		4,798
	$	27,064	$	34,507	$	24,267

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		12 Months Ended
	Mar. 12, 2013	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year.

Employee Benefit Plans - Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Net pension liability at beginning of period	$ 3,502	$ 8,795
Employer contributions	(2,413)	(2,267)
Net pension expense	(933)	283
Pension liability adjustment	4,012	(2,803)
Foreign currency translation (loss) gain	93	(506)
Net pension liability at end of period	$ 4,261	$ 3,502

Revenue - Additional Information (Detail) - USD ($)	12 Months Ended
Revenue - Additional Information (Detail) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Reductions to accounts receivable	$ (19,060,000)	$ (16,821,000)	$ (28,570,000)
Cost report receivables	13,723,000	10,340,000
Net adjustments to estimated cost report settlements resulted in (decreases) increases to revenue	(400,000)	500,000	200,000
Costs of providing charity care services	4,300,000	4,700,000	$ 5,300,000
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative-effect adjustment in retained earnings	0
Reductions to accounts receivable	$ 47,400,000	$ 47,000,000.0

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	December 31, 2019			December 31, 2018
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	346,750		$	365,750
Senior Secured Term B Loans		1,338,928			1,372,912
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		4,821			5,953
Less: unamortized debt issuance costs, discount and premium		(31,400	)		(41,128	)
		3,149,099			3,193,487
Less: current portion		(43,679	)		(34,112	)
Long-term debt	$	3,105,420		$	3,159,375

Summary of Aggregate Maturities of Long-Term Debt

The aggregate maturities of long-term debt at December 31, 2019 were as follows (in thousands):

2020	$	43,675
2021		483,501
2022		757,855
2023		1,505,468
2024		390,000
Thereafter		—
Total	$	3,180,499

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Segment Information - Additional Information (Detail)	12 Months Ended
Segment Information - Additional Information (Detail)	Dec. 31, 2019 Facility Bed State
Segment Reporting Information [Line Items]
Number of facilities \| Facility	585
Number of beds \| Bed	18,200
Number of operating states \| State	40
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	224
Number of beds \| Bed	9,500
Number of operating states \| State	40
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	361
Number of beds \| Bed	8,700

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2019, 2018 and 2017 (in thousands, except per share amounts):

	Year Ended December 31,
	2019		2018			2017
Numerator:
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	108,923	$	(175,750	)	$	199,835
Denominator:
Weighted average shares outstanding for basic earnings per share		87,612		87,288			86,948
Effects of dilutive instruments		204		—			112
Shares used in computing diluted earnings per common share		87,816		87,288			87,060
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	1.24	$	(2.01	)	$	2.30
Diluted	$	1.24	$	(2.01	)	$	2.30

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill:
Goodwill	$ 2,722,287	$ 2,751,174
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	2,396,412	2,751,174
Loss on impairment		(325,875)
Increase from contribution of redeemable noncontrolling interests	3,300	2,245
Increase from 2019 acquisitions	36,967
Foreign currency translation loss	12,452	(31,894)
Prior year purchase price adjustments		762
Goodwill	2,775,006	2,722,287
Accumulated impairment loss	(325,875)	(325,875)
Net goodwill, ending balance	2,449,131	2,396,412
U.S. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Goodwill	2,044,837	2,042,592
Net goodwill, beginning balance	2,044,837	2,042,592
Increase from contribution of redeemable noncontrolling interests	3,300	2,245
Increase from 2019 acquisitions	36,967
Goodwill	2,085,104	2,044,837
Net goodwill, ending balance	2,085,104	2,044,837
U.K. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Goodwill	677,450	708,582
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	351,575	708,582
Loss on impairment		(325,875)
Foreign currency translation loss	12,452	(31,894)
Prior year purchase price adjustments		762
Goodwill	689,902	677,450
Accumulated impairment loss	(325,875)	(325,875)
Net goodwill, ending balance	$ 364,027	$ 351,575

Equity - Additional Information (Detail) - shares	12 Months Ended
Equity - Additional Information (Detail) - shares	Dec. 31, 2019	Dec. 31, 2018
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000	10,000,000
Common stock, number of shares proposed to be issued	180,000,000	180,000,000
Common stock voting rights	one vote for each share
Maximum [Member]
Equity [Line Items]
Preferred stock, number of shares proposed to be issued	10,000,000
Common stock, number of shares proposed to be issued	180,000,000

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Noncontrolling Interest [Abstract]
Beginning Balance	$ 28,806	$ 22,417
Acquisition of redeemable noncontrolling interests	3,300	6,125
Net income attributable to noncontrolling interests	1,199	264
Distributions to noncontrolling interests	(154)
Ending Balance	$ 33,151	$ 28,806

Commitments and Contingencies - Additional Information (Detail) - West Virginia [Member] $ in Millions	3 Months Ended
	Jun. 30, 2019 USD ($) Facility
Loss Contingencies [Line Items]
Number of comprehensive treatment centers operates \| Facility	7
Amount paid to government \| $	$ 17.0

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Components of Provision for Income Taxes

Provision for income taxes consists of the following for the periods presented (in thousands):

	Year Ended December 31,
	2019			2018			2017
Current:
Federal	$	18,954		$	13,961		$	3,325
State		3,440			1,113			680
Foreign		1,692			1,172			1,832
Total current		24,086			16,246			5,837
Deferred:
Federal		(1,573	)		(7,176	)		27,179
State		2,509			(10	)		4,408
Foreign		844			(2,528	)		(215	)
Total deferred provision		1,780			(9,714	)		31,372
Provision for income taxes	$	25,866		$	6,532		$	37,209

Effective Income Tax Rate

A reconciliation of the U.S. federal statutory rate to the effective tax rate is as follows for the periods presented:

	Year Ended December 31,
	2019			2018			2017
U.S. federal statutory rate on income before income taxes		21.0	%		21.0	%		35.0	%
Impact of foreign operations		(15.3	)		9.5			(14.1	)
Impacts of SAB 118		—			6.7			—
Effects of statutory rate change		—			—			(8.5	)
State income taxes, net of federal tax effect		3.3			(1.4	)		2.1
Permanent differences		2.4			(4.1	)		1.8
Goodwill impairment		—			(36.6	)		—
Change in valuation allowance		2.9			(1.4	)		1.6
Unrecognized tax benefit release		0.3			3.1			(0.8	)
Interest disallowance		4.2			(2.2	)		—
Federal tax credits		(1.3	)		1.0			—
Other		1.5			0.5			(1.4	)
Effective income tax rate		19.0	%		(3.9	)%		15.7	%

Summary of Domestic and Foreign Components of Income (Loss) before Income Taxes

The domestic and foreign components of income (loss) before income taxes are as follows (in thousands):

	Year Ended December 31,
	2019		2018			2017
Foreign	$	61,921	$	(228,350	)	$	120,905
Domestic		74,067		59,396			115,893
Total	$	135,988	$	(168,954	)	$	236,798

Deferred Tax Assets and Liabilities

	December 31,
	2019			2018
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$	25,118		$	27,294
Bad debt allowance		996			898
Accrued compensation and severance		14,645			15,229
Pension reserves		724			595
Insurance reserves		16,485			13,994
Leases		3,436			5,374
Accrued expenses		1,496			4,231
Interest carryforwards		59,413			32,272
Lease liabilities		98,419			—
Other assets		2,562			2,284
Total gross deferred tax assets		223,294			102,171
Less: valuation allowance		(28,648	)		(24,079	)
Deferred tax assets		194,646			78,092
Deferred tax liabilities:
Fixed asset basis difference		(43,992	)		(48,698	)
Prepaid items		(2,163	)		(1,728	)
Intangible assets		(104,542	)		(87,628	)
Lease right-of-use assets		(99,677	)		—
Other liabilities		(12,793	)		(16,942	)
Total deferred tax liabilities		(263,167	)		(154,996	)
Total net deferred tax liability	$	(68,521	)	$	(76,904	)

Unrecognized Income Tax Benefits Net of Federal Benefit

A reconciliation of the beginning and ending amount of unrecognized income tax benefits net of the federal benefit is as follows (in thousands):

	2019			2018
Balance at January 1	$	713		$	6,104
Additions based on tax positions related to the current year		3,001			52
Reductions as a result of the lapse of applicable statutes of limitations and settlements with tax authorities		(1,273	)		(5,443	)
Balance at December 31	$	2,441		$	713

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2019	Feb. 28, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ACHC
Entity Registrant Name	ACADIA HEALTHCARE COMPANY, INC.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		88,493,519
Entity Public Float			$ 3.1
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for its 2020 annual meeting of stockholders to be held on May 7, 2020 are incorporated by reference into Part III of this Form 10-K.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $52.6 million at December 31, 2019, of which $4.7 million was included in other accrued liabilities and $47.9 million was included in other long-term liabilities. The professional and general liability reserve was $42.8 million at December 31, 2018, of which $5.0 million was included in other accrued liabilities and $37.8 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves

that are recoverable under the Company’s insurance policies. Such receivable was $8.5 million at December 31, 2019, of which $3.0 million was included in other current assets and $5.5 million was included in other assets, and such receivable was $8.2 million at December 31, 2018, of which $2.1 million was included in other current assets and $6.1 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $20.8 million at December 31, 2019, of which $10.0 million was included in accrued salaries and benefits and $10.8 million was included in other long-term liabilities, and such liability was $19.3 million at December 31, 2018, of which $10.0 million was included in accrued salaries and benefits and $9.3 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $164.0 million, $158.8 million and $143.0 million for the years ended years ended December 31, 2019, 2018 and 2017, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows.

The Company performed an impairment review of long-lived assets in the fourth quarter of 2019, which indicated the carrying amounts of certain long-lived assets in the Company’s facilities in the U.S. (the “U.S. Facilities”) and its facilities in the U.K. (the “U.K. Facilities”) may not be recoverable. This created a non-cash loss on impairment of $54.4 million for the year ended December 31, 2019. A 2018 impairment review resulted in a non-cash impairment of $12.0 million for the year ended December 31, 2018 related to certain U.K. Facilities. These items were recorded in loss on impairment on our consolidated statements of operations. No impairment was recorded for the year ended December 31, 2017.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of license and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable. The Company has two operating segments for segment reporting purpose, U.S. Facilities and U.K. Facilities, each of which represents a reporting unit for purposes of the Company’s goodwill impairment test.

Our annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2019 resulted in no impairment charges. The Company’s annual goodwill impairment test performed as of October 1, 2018 considered the recent financial performance, including the labor market pressures faced by the U.K. Facilities. The 2018 impairment test for the U.S. Facilities indicated estimated fair value exceeded carrying value, and therefore no impairment was recorded. The 2018 impairment test for the U.K. Facilities indicated carrying value exceeded the estimated fair value. The difference was recorded as a non-cash loss on impairment of $325.9 million for the year ended December 31, 2018 within loss on impairment in the consolidated statements of operations. The Company’s annual impairment tests of goodwill and other indefinite-lived intangible assets in 2017 resulted in no impairment charges.

In performing the goodwill impairment test, the Company used a combination of the income and market approaches to estimate fair value of our reporting units. Determining fair value requires substantial judgement and use of significant unobservable inputs, which are categorized as Level 3 fair value measurements. For the income approach, the Company used a discounted cash flow model in which cash flows are projected using internal forecasts over future periods, plus a terminal value, and are discounted to present value using a risk-adjusted rate of return. The Company’s internal forecasts include estimates of growth rates and profitability based on our current views of the long-term outlook of each reporting unit and may materially differ from actual results. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of each reporting unit. The discount rates used in its analysis range from 10.0% to 10.5% and correspond to the risks inherent in each reporting unit. For the market approach, we compared our reporting units to guideline companies actively traded in public markets and included a control premium, which was

based on acquisition premiums of selected companies similar to our reporting units. Estimating fair values of our reporting units includes substantial judgement and significant estimates and may materially differ from actual results. Changes in assumptions, industry or peer groups could negatively impact estimated fair value.

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2019		2018
Prepaid expenses	$	23,708	$	30,802
Other receivables		16,097		19,205
Cost report receivable		13,723		10,340
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		5,579		2,380
Inventory		4,759		5,055
Insurance receivable – current portion		3,030		2,049
Other		1,348		1,989
Other current assets	$	78,244	$	81,820

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2019		2018
Accrued expenses	$	50,614	$	44,938
Accrued interest		33,323		32,838
Unearned income		38,475		32,154
Finance lease liabilities		6,819		—
Insurance liability – current portion		4,731		4,956
Accrued property taxes		4,755		4,136
Income taxes payable		—		3,041
Accrued legal settlements		—		22,076
Other		2,443		7,087
Other accrued liabilities	$	141,160	$	151,226

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation .” The Company uses the Black-Scholes valuation model to determine grant-date fair value for equity awards and uses straight-line amortization of share-based compensation expense over the requisite service period of the respective awards. The fair values of restricted stock units are determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at their Monte-Carlo simulation value for units subject to market conditions.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options and non-vested shares, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is

realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Company has accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. The Company accrues for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Although Management believes that the positions taken on previously filed tax returns are reasonable, we nevertheless have established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by us resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect our potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

The Tax Act was enacted on December 22, 2017. The Tax Act reduced the U.S. federal corporate tax rate from 35% to 21% and included certain other changes. See additional disclosure described in Note 12 – Income Taxes.

Recent Accounting Pronouncements

In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-402 to determine which implementation costs to capitalize as assets. ASU 2018-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. Management is evaluating the impact of ASU 2018-15 on the Company’s consolidated financial statements.

In August 2017, FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”). ASU 2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU 2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. The Company adopted ASU 2017-12 on January 1, 2019. There is no significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss impairment methodology with a new methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. Management is evaluating the impact of ASU 2016-13 on the Company’s consolidated financial statements

In March 2016, the FASB issued ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. ASU 2016-02 requires application either retrospectively to each prior reporting period presented in the financial statements or retrospectively at the beginning of the period of adoption. The Company adopted ASU 2016-02 retrospectively at the beginning of the period of adoption. Prior periods have not been adjusted. On January 1, 2019, the Company recorded right-of-use assets and lease liabilities of $500.3 million and $526.6 million, respectively, as described in Note 8 – Leases.

Equity-Based Compensation

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

11. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At December 31, 2019, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 2,903,059 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $17.3 million, $22.0 million and $23.5 million in equity-based compensation expense for the years ended December 31, 2019, 2018 and 2017, respectively. Stock compensation expense for the years ended December 31, 2019, 2018 and 2017 included forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting targets of $(6.4) million, $(5.5) million and $(5.7) million, respectively. At December 31, 2019, there was $34.3 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.2 years.

At December 31, 2019, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $4.2 million and $7.0 million for the years ended December 31, 2019 and 2018, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2017, 2018 and 2019 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2017		1,000,946		$	48.42		7.46	$	8,166
Options granted		259,300			42.25		9.30		205
Options exercised		(87,367	)		25.92	N/A			1,636
Options cancelled		(198,313	)		54.71	N/A		N/A
Options outstanding at December 31, 2017		974,566			47.89		7.46		3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068		$	39.40		7.57	$	1,650
Options exercisable at December 31, 2018		534,164		$	44.98		5.73	$	2,386
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2019, 2018 and 2017:

	Year Ended December 31,
	2019			2018			2017
Weighted average grant-date fair value of options	$	17.59		$	13.67		$	14.39
Risk-free interest rate		2.4	%		2.2	%		2.0	%
Expected volatility		38	%		37	%		33	%
Expected life (in years)		5.0			5.1			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2017, 2018 and 2019 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		844,419		$	55.76
Granted		404,224			42.38
Cancelled		(145,981	)		55.03
Vested		(292,794	)		53.07
Unvested at December 31, 2017		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14

Restricted stock unit activity during 2017, 2018 and 2019 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		273,599		$	59.68
Granted		219,840			43.23
Cancelled		—			—
Vested		(132,530	)		58.67
Unvested at December 31, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2019 and 2018 are subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of

the targeted units based on the Company’s actual performance compared to the targets and, for 2019 and 2018 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts									$ 3,107,462	$ 3,012,442	$ 2,877,234
Provision for doubtful accounts											(40,918)
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	3,107,462	3,012,442	2,836,316
Salaries, wages and benefits									1,717,180	1,659,348	1,536,160
Professional fees									240,983	227,425	196,223
Supplies									123,061	119,314	114,439
Rents and leases									82,229	80,282	76,775
Other operating expenses									375,433	354,498	331,827
Depreciation and amortization									164,044	158,832	143,010
Interest expense, net									187,094	185,410	176,007
Debt extinguishment costs										1,815	810
Legal settlements expense					22,100					22,076
Loss on impairment	54,400				337,900				54,386	337,889
Transaction-related expenses									27,064	34,507	24,267
Total expenses									2,971,474	3,181,396	2,599,518
Income (loss) before income taxes	(10,248)	49,560	59,805	36,871	(341,336)	55,036	69,258	48,088	135,988	(168,954)	236,798
(Benefit from) provision for income taxes									25,866	6,532	37,209
Net income (loss)									110,122	(175,486)	199,589
Net income (loss) attributable to noncontrolling interests									(1,199)	(264)	246
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	108,923	(175,750)	199,835
Other comprehensive income:
Foreign currency translation (loss) gain									69,811	(127,521)	206,784
(Loss) gain on derivative instruments, net of tax of $(3.6) million, $12.7 million and $(22.9) million, respectively									(19,008)	36,799	(33,431)
Pension liability adjustment, net									(3,310)	2,463	2,099
Other comprehensive income (loss)									47,493	(88,259)	175,452
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									156,416	(264,009)	375,287
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits									17,307	22,001	23,467
Interest expense, net									76,138	65,588	61,872
Debt extinguishment costs										940	810
Total expenses									93,445	88,529	86,149
Income (loss) before income taxes									(93,445)	(88,529)	(86,149)
Equity in earnings of subsidiaries									174,216	(98,669)	259,282
(Benefit from) provision for income taxes									(29,351)	(11,712)	(26,456)
Net income (loss)									110,122	(175,486)	199,589
Net income (loss) attributable to Acadia Healthcare Company, Inc.									110,122	(175,486)	199,589
Other comprehensive income:
(Loss) gain on derivative instruments, net of tax of $(3.6) million, $12.7 million and $(22.9) million, respectively									(19,008)	36,799	(33,431)
Other comprehensive income (loss)									(19,008)	36,799	(33,431)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									91,114	(138,687)	166,158
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts											1,746,656
Provision for doubtful accounts											(35,636)
Revenue									1,882,518	1,788,757	1,711,020
Salaries, wages and benefits									1,018,267	965,419	902,180
Professional fees									107,115	98,441	93,991
Supplies									80,137	76,526	75,248
Rents and leases									34,443	33,101	33,365
Other operating expenses									243,478	225,446	217,900
Depreciation and amortization									81,105	74,341	66,482
Interest expense, net									92,538	92,983	81,274
Legal settlements expense										22,076
Loss on impairment									27,217
Transaction-related expenses									21,156	29,720	11,236
Total expenses									1,705,456	1,618,053	1,481,676
Income (loss) before income taxes									177,062	170,704	229,344
(Benefit from) provision for income taxes									52,903	19,045	69,882
Net income (loss)									124,159	151,659	159,462
Net income (loss) attributable to Acadia Healthcare Company, Inc.									124,159	151,659	159,462
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									124,159	151,659	159,462
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts											1,130,578
Provision for doubtful accounts											(5,282)
Revenue									1,224,944	1,223,685	1,125,296
Salaries, wages and benefits									681,606	671,928	610,513
Professional fees									133,868	128,984	102,232
Supplies									42,924	42,788	39,191
Rents and leases									47,786	47,181	43,410
Other operating expenses									131,955	129,052	113,927
Depreciation and amortization									82,939	84,491	76,528
Interest expense, net									18,418	26,839	32,861
Debt extinguishment costs										875
Loss on impairment									27,169	337,889
Transaction-related expenses									5,908	4,787	13,031
Total expenses									1,172,573	1,474,814	1,031,693
Income (loss) before income taxes									52,371	(251,129)	93,603
(Benefit from) provision for income taxes									2,314	(801)	(6,217)
Net income (loss)									50,057	(250,328)	99,820
Net income (loss) attributable to noncontrolling interests									(1,199)	(264)	246
Net income (loss) attributable to Acadia Healthcare Company, Inc.									48,858	(250,592)	100,066
Other comprehensive income:
Foreign currency translation (loss) gain									69,811	(127,521)	206,784
Pension liability adjustment, net									(3,310)	2,463	2,099
Other comprehensive income (loss)									66,501	(125,058)	208,883
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									115,359	(375,650)	308,949
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries									(174,216)	98,669	(259,282)
Net income (loss)									(174,216)	98,669	(259,282)
Net income (loss) attributable to Acadia Healthcare Company, Inc.									(174,216)	98,669	(259,282)
Other comprehensive income:
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.									$ (174,216)	$ 98,669	$ (259,282)

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		12 Months Ended
	Jul. 01, 2014	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year.

Noncontrolling Interests - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	5
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	$ 3,107,462	$ 3,012,442	$ 2,836,316
Income (loss) before income taxes	(10,248)	49,560	59,805	36,871	(341,336)	55,036	69,258	48,088	135,988	(168,954)	236,798
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	$ 108,923	$ (175,750)	$ 199,835
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ (0.13)	$ 0.49	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$ (0.13)	$ 0.48	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,715,591	87,444,473
Common stock, shares outstanding	87,715,591	87,444,473

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 124,192	$ 50,510
Accounts receivable, net	339,775	318,087
Other current assets	78,244	81,820
Total current assets	542,211	450,417
Property and equipment, net	3,224,034	3,107,766
Goodwill	2,449,131	2,396,412	$ 2,751,174
Intangible assets, net	90,357	88,990
Deferred tax assets – noncurrent	3,339	3,468
Derivative instruments		60,524
Operating lease right-of-use assets	501,837
Other assets	68,233	64,927
Total assets	6,879,142	6,172,504
Current liabilities:
Current portion of long-term debt	43,679	34,112
Accounts payable	127,045	117,740
Accrued salaries and benefits	122,552	113,299
Current portion of operating lease liabilities	29,140
Other accrued liabilities	141,160	151,226
Total current liabilities	463,576	416,377
Long-term debt	3,105,420	3,159,375
Deferred tax liabilities – noncurrent	71,860	80,372
Operating lease liabilities	502,252
Derivative instrument liabilities	68,915
Other liabilities	128,587	154,267
Total liabilities	4,340,610	3,810,391
Redeemable noncontrolling interests	33,151	28,806	22,417
Total equity	2,505,381	2,333,307	$ 2,572,871	$ 2,167,724
Total liabilities and equity	6,879,142	6,172,504
Parent [Member]
Current assets:
Deferred tax assets – noncurrent	1,403	1,841
Derivative instruments		60,524
Investment in subsidiaries	5,521,340	5,190,771
Other assets	233,975	306,495
Total assets	5,756,718	5,559,631
Current liabilities:
Current portion of long-term debt	43,679	34,112
Other accrued liabilities	33,323	32,837
Total current liabilities	77,002	66,949
Long-term debt	3,105,420	3,159,375
Derivative instrument liabilities	68,915
Total liabilities	3,251,337	3,226,324
Total equity	2,505,381	2,333,307
Total liabilities and equity	5,756,718	5,559,631
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	98,943	32,471
Accounts receivable, net	266,864	248,218
Other current assets	61,508	60,160
Total current assets	427,315	340,849
Property and equipment, net	1,313,830	1,219,803
Goodwill	1,992,344	1,936,057
Intangible assets, net	58,291	56,611
Operating lease right-of-use assets	97,396
Other assets	48,949	52,824
Total assets	3,938,125	3,606,144
Current liabilities:
Accounts payable	87,165	79,463
Accrued salaries and benefits	89,483	84,150
Current portion of operating lease liabilities	17,967
Other accrued liabilities	22,672	42,062
Total current liabilities	217,287	205,675
Deferred tax liabilities – noncurrent	21,858	31,874
Operating lease liabilities	85,365
Other liabilities	110,445	107,866
Total liabilities	434,955	345,415
Total equity	3,503,170	3,260,729
Total liabilities and equity	3,938,125	3,606,144
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	25,249	18,039
Accounts receivable, net	72,911	69,869
Other current assets	16,736	21,660
Total current assets	114,896	109,568
Property and equipment, net	1,910,204	1,887,963
Goodwill	456,787	460,355
Intangible assets, net	32,066	32,379
Deferred tax assets – noncurrent	3,339	3,468
Operating lease right-of-use assets	404,441
Other assets	13,127	9,548
Total assets	2,934,860	2,503,281
Current liabilities:
Accounts payable	39,880	38,277
Accrued salaries and benefits	33,069	29,149
Current portion of operating lease liabilities	11,173
Other accrued liabilities	85,165	76,327
Total current liabilities	169,287	143,753
Long-term debt	227,818	303,940
Deferred tax liabilities – noncurrent	51,405	50,339
Operating lease liabilities	416,887
Other liabilities	18,142	46,401
Total liabilities	883,539	544,433
Redeemable noncontrolling interests	33,151	28,806
Total equity	2,018,170	1,930,042
Total liabilities and equity	2,934,860	2,503,281
Consolidating Adjustments [Member]
Current assets:
Deferred tax assets – noncurrent	(1,403)	(1,841)
Investment in subsidiaries	(5,521,340)	(5,190,771)
Other assets	(227,818)	(303,940)
Total assets	(5,750,561)	(5,496,552)
Current liabilities:
Long-term debt	(227,818)	(303,940)
Deferred tax liabilities – noncurrent	(1,403)	(1,841)
Total liabilities	(229,221)	(305,781)
Total equity	(5,521,340)	(5,190,771)
Total liabilities and equity	$ (5,750,561)	$ (5,496,552)

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
(Loss) gain on derivative instruments, tax	$ (3.6)	$ 12.7	$ (22.9)
Pension liability adjustment, tax	$ (0.6)	$ 0.3	$ 0.4

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule Of Leases On Consolidated Balance Sheet

At December 31, 2019, the Company recorded the following on the consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	44,370
Operating lease right-of-use assets	Operating lease right-of-use assets		501,837
Total		$	546,207

Lease Liabilities	Balance Sheet Classification	December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	6,819
Operating lease liabilities	Current portion of operating lease liabilities		29,140
Noncurrent:
Finance lease liabilities	Other liabilities		43,662
Operating lease liabilities	Operating lease liabilities		502,252
Total		$	581,873

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates at December 31, 2019 were as follows:


Weighted-average remaining lease term (in years):
Finance	6.9
Operating	19.4

Weighted-average discount rate:
Finance		6.4	%
Operating		6.3	%

Schedule of Lease Cost

The Company recorded the following lease costs for the year ended December 31, 2019 (in thousands):


Finance lease costs:
Depreciation of leased assets		4,526
Interest of lease liabilities		3,991
Total finance lease costs	$	8,517

Operating lease costs		64,958
Variable lease costs		5,407
Short term lease costs		5,497
Other lease costs		6,367
Total rents and leases	$	82,229

Total lease costs	$	90,746

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2019 (in thousands):

	Finance Leases		Operating Leases
2020	$	7,494	$	61,857
2021		35,624		58,279
2022		2,681		53,395
2023		1,369		49,714
2024		1,007		47,505
Thereafter		25,088		689,931
Total minimum lease payments		73,263		960,681
Less: amount of lease payments representing interest		22,782		429,289
Present value of future minimum lease payments		50,481		531,392
Less: Current portion of lease liabilities		6,819		29,140
Noncurrent lease liabilities	$	43,662	$	502,252

Schedule Of Supplemental Data

Supplemental data for the year ended December 31, 2019 was as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	62,122
Operating cash flows for finance leases	$	3,991
Financing cash flows for finance leases	$	3,270

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	21,809
Finance leases	$	3,234

Noncontrolling Interests

12 Months Ended

Dec. 31, 2019

Noncontrolling Interest [Abstract]

Noncontrolling Interests

16. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At December 31, 2019, the Company operated five facilities and owns between approximately 60% and 86% of the equity interests, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2018	$	22,417
Acquisition of redeemable noncontrolling interests		6,125
Net income attributable to noncontrolling interests		264
Balance at December 31, 2018		28,806
Acquisition of redeemable noncontrolling interests		3,300
Net income attributable to noncontrolling interests		1,199
Distributions to noncontrolling interests		(154	)
Balance at December 31, 2019	$	33,151

Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Summary of the Activity in Unearned Revenue in the U.K. Facilities

A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2018	$	31,239
Payments received		172,666
Revenue recognized		(167,811	)
Foreign currency translation loss		485
Balance at December 31, 2019	$	36,579

U.S. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2019		2018		2017
Acute inpatient psychiatric facilities	$	912,097	$	814,124	$	757,211
Specialty treatment facilities		788,232		761,017		725,151
Residential treatment centers		286,959		293,053		284,637
Outpatient community-based facilities		21,093		36,501		42,845
Revenue	$	2,008,381	$	1,904,695	$	1,809,844

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities for the years ended December 31, 2019, 2018 and 2017 (in thousands):

	Year Ended December 31,
	2019					2018					2017
	Amount		%			Amount		%			Amount			%
Commercial	$	565,350		28.2	%	$	573,089		30.1	%	$	569,242			30.8	%
Medicare		294,691		14.7	%		280,340		14.7	%		281,270			15.2	%
Medicaid		1,007,102		50.1	%		893,644		46.9	%		796,375			43.0	%
Self-Pay		118,716		5.9	%		134,054		7.1	%		169,727			9.2	%
Other		22,522		1.1	%		23,568		1.2	%		33,942			1.8	%
Revenue before provision for doubtful accounts		2,008,381		100.0	%		1,904,695		100.0	%		1,850,556			100.0	%
Provision for doubtful accounts		—					—					(40,712	)
Revenue	$	2,008,381				$	1,904,695				$	1,809,844

U.K. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.K. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2019		2018		2017
Healthcare facilities	$	607,053	$	614,994	$	566,482
Education and Children’s Services		183,195		187,306		165,874
Adult Care facilities		308,833		305,447		294,116
Revenue	$	1,099,081	$	1,107,747	$	1,026,472

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities for the years ended December 31, 2019, 2018 and 2017 (in thousands):

	Year Ended December 31,
	2019					2018					2017
	Amount		%			Amount		%			Amount			%
U.K. public funded sources	$	991,353		90.2	%	$	1,000,828		90.3	%	$	922,159			89.8	%
Self-Pay		105,430		9.6	%		104,824		9.5	%		95,687			9.3	%
Other		2,298		0.2	%		2,095		0.2	%		8,832			0.9	%
Revenue before provision for doubtful accounts		1,099,081		100.0	%		1,107,747		100.0	%		1,026,678			100.0	%
Provision for doubtful accounts		—					—					(206	)
Revenue	$	1,099,081				$	1,107,747				$	1,026,472

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

8. Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

In March 2016, the FASB issued ASU 2016-02. ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 retrospectively at the beginning of the period of adoption. Prior periods have not been adjusted.

The Company has elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs. The Company also elected the accounting policy practical expedients by class of underlying asset to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

On January 1, 2019, the Company recorded right-of-use assets and lease liabilities on the consolidated balance sheet of $500.3 million and $526.6 million, respectively, for non-cancelable real estate operating leases with original lease terms in excess of one year. Finance leases remained on the consolidated balance sheets as required by previous accounting guidance. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the later of the lease commencement date or January 1, 2019. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms.

Lease Position

At December 31, 2019, the Company recorded the following on the consolidated balance sheet (in thousands):

Right-of-Use Assets	Balance Sheet Classification	December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	44,370
Operating lease right-of-use assets	Operating lease right-of-use assets		501,837
Total		$	546,207

Lease Liabilities	Balance Sheet Classification	December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	6,819
Operating lease liabilities	Current portion of operating lease liabilities		29,140
Noncurrent:
Finance lease liabilities	Other liabilities		43,662
Operating lease liabilities	Operating lease liabilities		502,252
Total		$	581,873

Weighted-average remaining lease terms and discount rates at December 31, 2019 were as follows:


Weighted-average remaining lease term (in years):
Finance	6.9
Operating	19.4

Weighted-average discount rate:
Finance		6.4	%
Operating		6.3	%

Lease Costs

The Company recorded the following lease costs for the year ended December 31, 2019 (in thousands):


Finance lease costs:
Depreciation of leased assets		4,526
Interest of lease liabilities		3,991
Total finance lease costs	$	8,517

Operating lease costs		64,958
Variable lease costs		5,407
Short term lease costs		5,497
Other lease costs		6,367
Total rents and leases	$	82,229

Total lease costs	$	90,746

Other

Undiscounted cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2019 (in thousands):

	Finance Leases		Operating Leases
2020	$	7,494	$	61,857
2021		35,624		58,279
2022		2,681		53,395
2023		1,369		49,714
2024		1,007		47,505
Thereafter		25,088		689,931
Total minimum lease payments		73,263		960,681
Less: amount of lease payments representing interest		22,782		429,289
Present value of future minimum lease payments		50,481		531,392
Less: Current portion of lease liabilities		6,819		29,140
Noncurrent lease liabilities	$	43,662	$	502,252

Supplemental data for the year ended December 31, 2019 was as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	62,122
Operating cash flows for finance leases	$	3,991
Financing cash flows for finance leases	$	3,270

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	21,809
Finance leases	$	3,234

Segment Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment Information

17. Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its U.S. Facilities and its U.K. Facilities separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At December 31, 2019, the U.S. Facilities included 224 behavioral healthcare facilities with approximately 9,500 beds in 40 states and Puerto Rico, and the U.K. Facilities included 361 behavioral healthcare facilities with approximately 8,700 beds in the U.K.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Year Ended December 31,
	2019			2018			2017
Revenue:
U.S. Facilities	$	2,008,381		$	1,904,695		$	1,809,844
U.K. Facilities		1,099,081			1,107,747			1,026,472
Corporate and Other		—			—			—
	$	3,107,462		$	3,012,442		$	2,836,316
Segment EBITDA (1) :
U.S. Facilities	$	503,358		$	488,207		$	475,260
U.K. Facilities		166,693			185,755			198,566
Corporate and Other		(84,168	)		(80,386	)		(69,467	)
	$	585,883		$	593,576		$	604,359

	Year Ended December 31,
	2019			2018			2017
Segment EBITDA(1)	$	585,883		$	593,576		$	604,359
Plus (less):
Equity-based compensation expense		(17,307	)		(22,001	)		(23,467	)
Debt extinguishment costs		—			(1,815	)		(810	)
Legal settlements expense		—			(22,076	)		—
Loss on impairment		(54,386	)		(337,889	)		—
Transaction-related expenses		(27,064	)		(34,507	)		(24,267	)
Interest expense, net		(187,094	)		(185,410	)		(176,007	)
Depreciation and amortization		(164,044	)		(158,832	)		(143,010	)
Income (loss) before income taxes	$	135,988		$	(168,954	)	$	236,798

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2018
Goodwill	$	2,042,592	$	708,582		$	—	$	2,751,174
Accumulated impairment loss		—		—			—		—
Net goodwill at January 1, 2018		2,042,592		708,582			—		2,751,174
Loss on impairment		—		(325,875	)		—		(325,875	)
Increase from contribution of redeemable noncontrolling interests		2,245		—			—		2,245
Foreign currency translation loss		—		(31,894	)		—		(31,894	)
Prior year purchase price adjustments		—		762			—		762
Balance at December 31, 2018
Goodwill		2,044,837		677,450			—		2,722,287
Accumulated impairment loss		—		(325,875	)		—		(325,875	)
Net goodwill at December 31, 2018		2,044,837		351,575			—		2,396,412
Increase from contribution of redeemable noncontrolling interests		3,300		—			—		3,300
Increase from 2019 acquisitions		36,967		—			—		36,967
Foreign currency translation gain		—		12,452			—		12,452
Balance at December 31, 2019
Goodwill		2,085,104		689,902			—		2,775,006
Accumulated impairment loss		—		(325,875	)		—		(325,875	)
Net goodwill at December 31, 2019	$	2,085,104	$	364,027		$	—	$	2,449,131

	December 31,
	2019		2018
Assets (2) :
U.S. Facilities	$	4,037,968	$	3,779,040
U.K. Facilities		2,610,357		2,175,809
Corporate and Other		230,817		217,655
	$	6,879,142	$	6,172,504

(1)

(2)

Other Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

7. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2019 and 2018 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2019		December 31, 2018		December 31, 2019			December 31, 2018
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,131		1,147		(1,131	)		(1,147	)
		3,231		3,247		(3,231	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,455		12,343		—			—
Trade names		60,831		60,109		—			—
Certificates of need		17,071		16,538		—			—
		90,357		88,990		—			—
Total	$	93,588	$	92,237	$	(3,231	)	$	(3,247	)

All the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Derivatives

12 Months Ended

Dec. 31, 2019

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

13. Derivatives

The Company entered into foreign currency forward contracts during the years ended December 31, 2019 and 2018 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £449.3 million. In August 2019, the Company terminated its existing net investment cross currency swap derivatives of $105.0 million. Cash received from the termination of the cross currency swap derivatives is included in investing activities in the consolidated statements of cash flows. The related gain from this termination is included in accumulated other comprehensive loss in accordance with ASC 815-30-40-1.

In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million.

The Company has designated the cross currency swap agreements and certain forward contracts entered into during 2018 and 2019 as qualifying hedging instruments and is accounting for these as net investment hedges. The fair values of these derivatives at December 31, 2019 and 2018 of $(68.9) million and $60.5 million, respectively, are recorded as derivative instrument liabilities and derivative instrument assets, respectively, on the consolidated balance sheets. During the year ended 2019, the Company elected the spot method for recording its net investment hedges. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense on the consolidated statements of operations. Gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the consolidated statements of cash flows.

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue before provision for doubtful accounts									$ 3,107,462	$ 3,012,442	$ 2,877,234
Provision for doubtful accounts											(40,918)
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	3,107,462	3,012,442	2,836,316
Salaries, wages and benefits (including equity-based compensation expense of $17,307, $22,001 and $23,467, respectively)									1,717,180	1,659,348	1,536,160
Professional fees									240,983	227,425	196,223
Supplies									123,061	119,314	114,439
Rents and leases									82,229	80,282	76,775
Other operating expenses									375,433	354,498	331,827
Depreciation and amortization									164,044	158,832	143,010
Interest expense, net									187,094	185,410	176,007
Debt extinguishment costs										1,815	810
Legal settlements expense					22,100					22,076
Loss on impairment	54,400				337,900				54,386	337,889
Transaction-related expenses									27,064	34,507	24,267
Total expenses									2,971,474	3,181,396	2,599,518
Income (loss) before income taxes	(10,248)	49,560	59,805	36,871	(341,336)	55,036	69,258	48,088	135,988	(168,954)	236,798
Provision for income taxes									25,866	6,532	37,209
Net income (loss)									110,122	(175,486)	199,589
Net (income) loss attributable to noncontrolling interests									(1,199)	(264)	246
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	$ 108,923	$ (175,750)	$ 199,835
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ (0.13)	$ 0.49	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30
Diluted	$ (0.13)	$ 0.48	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30
Weighted-average shares outstanding:
Basic									87,612	87,288	86,948
Diluted									87,816	87,288	87,060

Revenue - Schedule of U.K. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 3,107,462	$ 3,012,442	$ 2,877,234
Provision for doubtful accounts											(40,918)
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	3,107,462	3,012,442	2,836,316
U.K. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									1,099,081	1,107,747	1,026,678
Provision for doubtful accounts											(206)
Revenue									$ 1,099,081	$ 1,107,747	$ 1,026,472
Revenue before provision for doubtful accounts, Percentage									100.00%	100.00%	100.00%
U.K. Facilities [Member] \| U.K. Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 991,353	$ 1,000,828	$ 922,159
Revenue before provision for doubtful accounts, Percentage									90.20%	90.30%	89.80%
U.K. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 105,430	$ 104,824	$ 95,687
Revenue before provision for doubtful accounts, Percentage									9.60%	9.50%	9.30%
U.K. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts									$ 2,298	$ 2,095	$ 8,832
Revenue before provision for doubtful accounts, Percentage									0.20%	0.20%	0.90%

Accumulated Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ (3.6)	$ 12.7	$ (22.9)
Pension liability adjustment, tax	$ (0.6)	$ 0.3	$ 0.4

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands														3 Months Ended				12 Months Ended
	Nov. 15, 2019	Feb. 27, 2019	Feb. 06, 2019	Apr. 17, 2018	Mar. 29, 2018	Mar. 22, 2018	Mar. 21, 2018	Dec. 29, 2017	May 10, 2017	May 09, 2017	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 15, 2014
Debt Instrument [Line Items]
Debt extinguishment costs																			$ (1,815)	$ (810)
Term loan repayments	$ 20,000			$ 15,000				$ 22,500
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA																					$ 50,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit					$ 400,000
Tranche B-1 Repricing Amendment [Member]
Debt Instrument [Line Items]
Term loan repayments								7,700
Tranche B-2 Repricing Amendment [Member]
Debt Instrument [Line Items]
Term loan repayments								$ 14,800
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Term loan repayments	7,000			5,100
Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Term loan repayments	$ 13,000			$ 9,900
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings																		2.50%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings																		1.50%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement												Dec. 31, 2012	Apr. 01, 2011
Amount available under revolving line of credit																		$ 485,100
Debt instrument maturity date											Nov. 30, 2021									Feb. 11, 2022
Term loan repayments																	$ 1,200
Amended and Restated Senior Credit Facility [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan principal repayments											$ 7,100
Term loan repayments														$ 1,200
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2021 [Member]
Debt Instrument [Line Items]
Term loan principal repayments											$ 9,500
Amended and Restated Senior Credit Facility [Member] \| March 31, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments																$ 1,200
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments															$ 1,200
Amended and Restated Senior Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Standby letters of credit outstanding																		$ 14,900
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments																	$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan repayments														$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments																$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments															$ 2,300
Amended and Restated Senior Credit Facility [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Debt extinguishment costs									$ 800
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Debt extinguishment costs						$ 900
Revolving credit facility applicable rate					0.25%
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit					$ 500,000
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit					$ 380,000
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																		1.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings									2.75%	3.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings						2.50%	2.75%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																		0.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings									1.75%	2.00%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings						1.50%	1.75%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings																		2.50%
Eleventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement			Feb. 06, 2019
Twelfth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement		Feb. 27, 2019

Leases - Schedule of Lease Cost (Detail) $ in Thousands	12 Months Ended
Leases - Schedule of Lease Cost (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Finance lease costs:
Depreciation of leased assets	$ 4,526
Interest of lease liabilities	3,991
Total finance lease costs	8,517
Operating lease costs	64,958
Variable lease costs	5,407
Short term lease costs	5,497
Other lease costs	6,367
Total rents and leases	82,229
Total lease costs	$ 90,746

Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Equity

10. Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The board of directors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders.

Common Stock

The Company’s amended and restated certificate of incorporation provides that up to 180,000,000 shares of common stock may be issued. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Amended and Restated Senior Credit Facility imposes restrictions on the Company’s ability to pay dividends.

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net income (Loss) attributable to Acadia Healthcare Company, Inc. stockholders	$ (11,254)	$ 42,566	$ 48,140	$ 29,471	$ (331,637)	$ 46,232	$ 58,836	$ 50,819	$ 108,923	$ (175,750)	$ 199,835
Denominator:
Weighted average shares outstanding for basic earnings per share									87,612	87,288	86,948
Effects of dilutive instruments									204		112
Shares used in computing diluted earnings per common share									87,816	87,288	87,060
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ (0.13)	$ 0.49	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30
Diluted	$ (0.13)	$ 0.48	$ 0.55	$ 0.34	$ (3.80)	$ 0.53	$ 0.67	$ 0.58	$ 1.24	$ (2.01)	$ 2.30

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Accumulated Other Comprehensive Loss

19. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments			Pension Plan			Total
Balance at January 1, 2017	$	(584,081	)	$	40,598		$	(6,087	)	$	(549,570	)
Foreign currency translation gain (loss)		207,341			—			(557	)		206,784
Loss on derivative instruments, net of tax of $(22.9) million		—			(33,431	)		—			(33,431	)
Pension liability adjustment, net of tax of $0.4 million		—			—			2,099			2,099
Balance at December 31, 2017		(376,740	)		7,167			(4,545	)		(374,118	)
Foreign currency translation (loss) gain		(127,788	)		—			267			(127,521	)
Gain on derivative instruments, net of tax of $12.7 million		—			36,799			—			36,799
Pension liability adjustment, net of tax of $0.3 million		—			—			2,463			2,463
Balance at December 31, 2018		(504,528	)		43,966			(1,815	)		(462,377	)
Foreign currency translation gain (loss)		69,895			—			(84	)		69,811
Loss on derivative instruments, net of tax of $(3.6) million		—			(19,008	)		—			(19,008	)
Pension liability adjustment, net of tax of $(0.6) million		—			—			(3,310	)		(3,310	)
Balance at December 31, 2019	$	(434,633	)	$	24,958		$	(5,209	)	$	(414,884	)

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net income (loss)	$ 110,122	$ (175,486)	$ 199,589
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities:
Depreciation and amortization	164,044	158,832	143,010
Amortization of debt issuance costs	11,987	10,456	9,855
Equity-based compensation expense	17,307	22,001	23,467
Deferred income taxes	1,780	(9,714)	31,372
Debt extinguishment costs		1,815	810
Legal settlements expense		22,076
Loss on impairment	54,386	337,889
Other	4,035	12,371	11,412
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(19,060)	(16,821)	(28,570)
Other current assets	(1,344)	13,864	20,808
Other assets	(73)	2,762	(3,176)
Accounts payable and other accrued liabilities	(21,354)	26,054	(10,113)
Accrued salaries and benefits	7,820	15,748	(8,988)
Other liabilities	3,254	(5,219)	11,794
Net cash provided by continuing operating activities	332,904	416,628	401,270
Net cash used in discontinued operating activities		(2,548)	(1,693)
Net cash provided by operating activities	332,904	414,080	399,577
Investing activities:
Cash paid for acquisitions, net of cash acquired	(45,677)		(18,191)
Cash paid for capital expenditures	(284,682)	(341,462)	(274,177)
Cash paid for real estate acquisitions	(7,618)	(18,383)	(41,057)
Settlement of foreign currency derivatives	105,008
Proceeds from sale of property and equipment	18,076	8,248	5,252
Other	13,752	(9,367)	(8,353)
Net cash used in investing activities	(201,141)	(360,964)	(336,526)
Financing activities:
Borrowings on revolving credit facility	76,573
Principal payments on revolving credit facility	(76,573)
Principal payments on long-term debt	(52,984)	(39,738)	(57,305)
Repayment of long-term debt		(21,920)
Common stock withheld for minimum statutory taxes, net	(1,649)	(3,407)	(3,455)
Distributions to noncontrolling interests	(154)
Other	(6,840)	(2,265)	686
Net cash used in financing activities	(61,627)	(67,330)	(60,074)
Effect of exchange rate changes on cash	3,546	(2,566)	7,250
Net increase (decrease) in cash and cash equivalents	73,682	(16,780)	10,227
Cash and cash equivalents at beginning of the period	50,510	67,290	57,063
Cash and cash equivalents at end of the period	124,192	50,510	67,290
Supplemental Cash Flow Information:
Cash paid for interest	173,239	175,204	159,098
Cash paid for income taxes	35,463	$ 6,720	10,291
Effect of acquisitions:
Assets acquired, excluding cash	49,715		19,649
Liabilities assumed	(4,038)		(1,458)
Cash paid for acquisitions, net of cash acquired	$ 45,677		$ 18,191

Employee Benefit Plans - Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 66,468	$ 57,993
Fair value of plan assets	62,207	54,491
Unfunded liability	$ 4,261	$ 3,502	$ 8,795

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

Insurance

Property and Equipment and Other Long-Lived Assets

Goodwill and Indefinite-Lived Intangible Assets

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2019		2018
Prepaid expenses	$	23,708	$	30,802
Other receivables		16,097		19,205
Cost report receivable		13,723		10,340
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		5,579		2,380
Inventory		4,759		5,055
Insurance receivable – current portion		3,030		2,049
Other		1,348		1,989
Other current assets	$	78,244	$	81,820

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2019		2018
Accrued expenses	$	50,614	$	44,938
Accrued interest		33,323		32,838
Unearned income		38,475		32,154
Finance lease liabilities		6,819		—
Insurance liability – current portion		4,731		4,956
Accrued property taxes		4,755		4,136
Income taxes payable		—		3,041
Accrued legal settlements		—		22,076
Other		2,443		7,087
Other accrued liabilities	$	141,160	$	151,226

Stock Compensation

Earnings Per Share

Income Taxes

realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

Recent Accounting Pronouncements

Revenue - Summary of the Activity in Unearned Revenue (Detail) - U.K. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 31,239
Payments received	172,666
Revenue recognized	(167,811)
Foreign currency translation loss	485
Ending Balance	$ 36,579

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating losses and tax credit carryforwards – federal and state	$ 25,118	$ 27,294
Bad debt allowance	996	898
Accrued compensation and severance	14,645	15,229
Pension reserves	724	595
Insurance reserves	16,485	13,994
Leases	3,436	5,374
Accrued expenses	1,496	4,231
Interest carryforwards	59,413	32,272
Lease liabilities	98,419
Other assets	2,562	2,284
Total gross deferred tax assets	223,294	102,171
Less: valuation allowance	(28,648)	(24,079)
Deferred tax assets	194,646	78,092
Deferred tax liabilities:
Fixed asset basis difference	(43,992)	(48,698)
Prepaid items	(2,163)	(1,728)
Intangible assets	(104,542)	(87,628)
Lease right-of-use assets	(99,677)
Other liabilities	(12,793)	(16,942)
Total deferred tax liabilities	(263,167)	(154,996)
Total net deferred tax liability	$ (68,521)	$ (76,904)

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Summary of Funded Status (Unfunded Liability) of Partnerships in Care Pension Plan Based Upon Actuarial Valuations

The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared at December 31, 2019 and 2018 (in thousands):

	2019		2018
Projected benefit obligation	$	66,468	$	57,993
Fair value of plan assets		62,207		54,491
Unfunded liability	$	4,261	$	3,502

Summary of Changes in Partnerships in Care Pension Plan Net Pension Liability

The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability at December 31, 2019 and 2018 (in thousands):

	2019			2018
Net pension liability at beginning of period	$	3,502		$	8,795
Employer contributions		(2,413	)		(2,267	)
Net pension expense		(933	)		283
Pension liability adjustment		4,012			(2,803	)
Foreign currency translation (loss) gain		93			(506	)
Net pension liability at end of period	$	4,261		$	3,502

Summary of Assumptions Used to Determine Plan Benefit obligation

A pension liability of $4.3 million and $3.5 million were recorded within other liabilities on the consolidated balance sheets at December 31, 2019 and 2018. The following assumptions were used to determine the plan benefit obligation:

Discount rate		1.9	%		2.8	%
Compensation increase rate		2.9	%		3.3	%
Measurement date	December 31, 2019			December 31, 2018

Assumptions used to determine the net periodic pension plan expense for the years ended December 31, 2019 and 2018 were as follows:

	2019			2018
Discount rate		1.9	%		2.8	%
Expected long-term rate of return on plan assets		1.9	%		2.8	%

Summary of Components of Net Pension Plan Expense

A summary of the components of net pension plan expense for the years ended December 31, 2019 and 2018 is as follows (in thousands):

	2019			2018
Interest cost on projected benefit obligation	$	1,605		$	1,602
Expected return on assets		(2,538	)		(1,319	)
Net pension expense	$	(933	)	$	283

Schedule of Weighted-Average Asset Allocation by Asset Category in Partnerships in Care Pension Plan

The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category at December 31, 2019 and 2018 were as follows:

	December 31, 2019			December 31, 2018
Cash and cash equivalents		1.4	%		1.3	%
U.K. government obligation		16.2	%		15.0	%
Annuity contracts		35.1	%		38.6	%
Equity securities		28.8	%		25.4	%
Debt securities		12.5	%		15.8	%
Other		6.0	%		3.9	%

Quarterly Information (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Quarterly Information (Unaudited)

20. Quarterly Information (Unaudited)

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2019 and 2018. Management believes that all necessary adjustments have been included in the amounts stated below for a fair presentation of the results of operations for the periods presented when read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2019 and 2018. Results of operations for a particular quarter are not necessarily indicative of results of operations for an annual period and are not predictive of future periods.

	Quarter Ended
	March 31,			June 30,		September 30,		December 31,
	(In thousands except per share amounts)
2019:
Revenue	$	760,617		$	789,362	$	777,251	$	780,232
Income before income taxes	$	36,871		$	59,805	$	49,560	$	(10,248	)
Net income attributable to Acadia Healthcare Company, Inc. stockholders	$	29,471		$	48,140	$	42,566	$	(11,254	)	⁽¹⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.34		$	0.55	$	0.49	$	(0.13	)	⁽¹⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.34		$	0.55	$	0.48	$	(0.13	)	⁽¹⁾
2018:
Revenue	$	742,241		$	765,738	$	760,916	$	743,547
Income (loss) before income taxes	$	48,088		$	69,258	$	55,036	$	(341,336	)
Net income (loss) attributable to Acadia Healthcare Company, Inc. stockholders	$	50,819	⁽²⁾	$	58,836	$	46,232	$	(331,637	)	⁽³⁾
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.58	⁽²⁾	$	0.67	$	0.53	$	(3.80	)	⁽³⁾
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders	$	0.58	⁽²⁾	$	0.67	$	0.53	$	(3.80	)	⁽³⁾

(1)	Includes a loss on impairment of $54.4 million.

(2)	Includes tax benefits of $10.5 million pursuant to a change in the Company’s provisional amounts recorded at December 31, 2017 related to the enactment of the Tax Act.

(3)	Includes loss on impairment of $337.9 million and legal settlements expense of $22.1 million.

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,224,034	$ 3,107,766
Operating Segment [Member] \| U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,400,000	1,400,000
Operating Segment [Member] \| U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,700,000	1,700,000
Corporate Reconciling Items and Eliminations [Member] \| Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 50,900	$ 44,900

Revenue - Schedule of U.K. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 780,232	$ 777,251	$ 789,362	$ 760,617	$ 743,547	$ 760,916	$ 765,738	$ 742,241	$ 3,107,462	$ 3,012,442	$ 2,836,316
U.K. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									1,099,081	1,107,747	1,026,472
U.K. Facilities [Member] \| Health Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									607,053	614,994	566,482
U.K. Facilities [Member] \| Education and Children's Services [Member]
Disaggregation of Revenue [Line Items]
Revenue									183,195	187,306	165,874
U.K. Facilities [Member] \| Adult Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue									$ 308,833	$ 305,447	$ 294,116

Employee Benefit Plans

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

18. Employee Benefit Plans

Defined Contribution Plan

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company recorded expense of $4.1 million, $3.5 million, and $0.2 million related to the 401(k) plan for the years ended December 31, 2019, 2018 and 2017, respectively.

Partnerships in Care Pension Plan

As part of the acquisition of Partnerships in Care on July 1, 2014, the Company assumed a frozen contributory defined benefit retirement plan (“Partnerships in Care Pension Plan”) covering substantially all of the employees of Partnerships in Care and its subsidiaries prior to May 1, 2005 at which time, the Partnerships in Care Plan was frozen to new participants. Effective May 2015, the active participants no longer accrue benefits. The benefits under the Partnerships in Care Pension Plan were primarily based on years of service and final average earnings.

The Company accounts for the Partnerships in Care Pension Plan in accordance with ASC 715-30 “Compensation — Defined Benefit Plans”, (“ASC 715-30”). In accordance with ASC 715-30, the Company recognizes the unfunded liability of the Partnerships in Care Pension Plan on the Company’s consolidated balance sheet and unrecognized gains (losses) and prior service credits (costs) as changes in other comprehensive income (loss). The measurement date of the Partnerships in Care Pension Plan’s assets and liabilities coincides with the Company’s year-end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases, when applicable, expected long-term returns on plan assets and consider expected age of retirement and mortality. Expected return on plan assets is determined by using the specific asset distribution at the measurement date.

The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared at December 31, 2019 and 2018 (in thousands):

	2019		2018
Projected benefit obligation	$	66,468	$	57,993
Fair value of plan assets		62,207		54,491
Unfunded liability	$	4,261	$	3,502

The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability at December 31, 2019 and 2018 (in thousands):

	2019			2018
Net pension liability at beginning of period	$	3,502		$	8,795
Employer contributions		(2,413	)		(2,267	)
Net pension expense		(933	)		283
Pension liability adjustment		4,012			(2,803	)
Foreign currency translation (loss) gain		93			(506	)
Net pension liability at end of period	$	4,261		$	3,502

Discount rate		1.9	%		2.8	%
Compensation increase rate		2.9	%		3.3	%
Measurement date	December 31, 2019			December 31, 2018

A summary of the components of net pension plan expense for the years ended December 31, 2019 and 2018 is as follows (in thousands):

	2019			2018
Interest cost on projected benefit obligation	$	1,605		$	1,602
Expected return on assets		(2,538	)		(1,319	)
Net pension expense	$	(933	)	$	283

Assumptions used to determine the net periodic pension plan expense for the years ended December 31, 2019 and 2018 were as follows:

	2019			2018
Discount rate		1.9	%		2.8	%
Expected long-term rate of return on plan assets		1.9	%		2.8	%

The Company recognizes changes in the funded status of the pension plan as a direct increase or decrease to stockholders’ equity through accumulated other comprehensive income. The accumulated other comprehensive income (loss) related to the Partnerships in Care Pension Plan, net of taxes, for the years ended December 31, 2019, 2018 and 2017 was $(5.2) million, $(1.8) million and $(4.5) million, respectively.

The trustees of the Partnerships in Care Pension Plan are required to invest assets in the best interest of the Partnerships in Care Pension Plan’s members and also ensure liquid assets are available to make benefit payments as they become due. Performance of the Partnerships in Care Pension Plan’s assets are monitored quarterly, at a minimum, and asset allocations are adjusted as needed. The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category at December 31, 2019 and 2018 were as follows:

	December 31, 2019			December 31, 2018
Cash and cash equivalents		1.4	%		1.3	%
U.K. government obligation		16.2	%		15.0	%
Annuity contracts		35.1	%		38.6	%
Equity securities		28.8	%		25.4	%
Debt securities		12.5	%		15.8	%
Other		6.0	%		3.9	%

At December 31, 2019 and 2018, the Partnerships in Care Pension Plan cash and cash equivalents were classified as Level 1 in the GAAP fair value hierarchy. Fair values were based on utilizing quoted prices (unadjusted) in active markets for identical assets. The U.K. government obligations, annuity contracts, equity securities, debt securities and other investments were classified as Level 2 in the GAAP fair value hierarchy. Fair values were based on data points that are observable, such as quoted prices, interest rates and yield curves.

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	$ 4,821	$ 5,953
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,821	5,953
Derivative instrument (liabilities) assets	(68,915)	60,524
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	1,668,062	1,715,338
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	149,254	148,657
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	297,761	296,946
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	644,771	643,289
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	384,430	383,304
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,821	5,953
Derivative instrument (liabilities) assets	(68,915)	60,524
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,668,062	1,715,338
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	149,441	147,542
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	299,994	283,583
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	655,249	609,516
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 398,366	$ 369,888

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 110,122	$ (175,486)	$ 199,589
Other comprehensive income (loss):
Foreign currency translation gain (loss)	69,811	(127,521)	206,784
(Loss) gain on derivative instruments, net of tax of $(3.6) million, $12.7 million and $(22.9) million, respectively	(19,008)	36,799	(33,431)
Pension liability adjustment, net of tax of $(0.6) million, $0.3 million and $0.4 million, respectively	(3,310)	2,463	2,099
Other comprehensive income (loss)	47,493	(88,259)	175,452
Comprehensive income (loss)	157,615	(263,745)	375,041
Comprehensive (income) loss attributable to noncontrolling interests	(1,199)	(264)	246
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$ 156,416	$ (264,009)	$ 375,287

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2017, 2018 and 2019 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2017		1,000,946		$	48.42		7.46	$	8,166
Options granted		259,300			42.25		9.30		205
Options exercised		(87,367	)		25.92	N/A			1,636
Options cancelled		(198,313	)		54.71	N/A		N/A
Options outstanding at December 31, 2017		974,566			47.89		7.46		3,802
Options granted		374,700			37.54		9.21		246
Options exercised		(20,989	)		17.83	N/A			383
Options cancelled		(128,737	)		50.83	N/A		N/A
Options outstanding at December 31, 2018		1,199,540			44.64		7.26		2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068		$	39.40		7.57	$	1,650
Options exercisable at December 31, 2018		534,164		$	44.98		5.73	$	2,386
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 2019, 2018 and 2017:

	Year Ended December 31,
	2019			2018			2017
Weighted average grant-date fair value of options	$	17.59		$	13.67		$	14.39
Risk-free interest rate		2.4	%		2.2	%		2.0	%
Expected volatility		38	%		37	%		33	%
Expected life (in years)		5.0			5.1			5.5

Restricted Stock Activity

Restricted stock activity during 2017, 2018 and 2019 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		844,419		$	55.76
Granted		404,224			42.38
Cancelled		(145,981	)		55.03
Vested		(292,794	)		53.07
Unvested at December 31, 2017		809,868		$	50.19
Granted		480,137			36.84
Cancelled		(88,989	)		47.57
Vested		(395,959	)		50.41
Unvested at December 31, 2018		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14

Restricted Stock Unit Activity

Restricted stock unit activity during 2017, 2018 and 2019 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		273,599		$	59.68
Granted		219,840			43.23
Cancelled		—			—
Vested		(132,530	)		58.67
Unvested at December 31, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at December 31, 2018		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89

Employee Benefit Plans - Summary of Assumptions Used to Determine Plan Benefit Obligation (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member]	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Discount rate	1.90%	2.80%
Compensation increase rate	2.90%	3.30%

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	December 31,
	2019		2018
Prepaid expenses	$	23,708	$	30,802
Other receivables		16,097		19,205
Cost report receivable		13,723		10,340
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		5,579		2,380
Inventory		4,759		5,055
Insurance receivable – current portion		3,030		2,049
Other		1,348		1,989
Other current assets	$	78,244	$	81,820

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	December 31,
	2019		2018
Accrued expenses	$	50,614	$	44,938
Accrued interest		33,323		32,838
Unearned income		38,475		32,154
Finance lease liabilities		6,819		—
Insurance liability – current portion		4,731		4,956
Accrued property taxes		4,755		4,136
Income taxes payable		—		3,041
Accrued legal settlements		—		22,076
Other		2,443		7,087
Other accrued liabilities	$	141,160	$	151,226

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets:
Assets	$ 6,879,142	$ 6,172,504
U.S. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	4,037,968	3,779,040
U.K. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	2,610,357	2,175,809
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 230,817	$ 217,655

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	1,199,540	974,566	1,000,946
Options granted	605,200	374,700	259,300
Options exercised	(55,671)	(20,989)	(87,367)
Options cancelled	(389,001)	(128,737)	(198,313)
Options outstanding, Ending balance	1,360,068	1,199,540	974,566	1,000,946
Options exercisable, Ending balance	513,290	534,164
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 44.64	$ 47.89	$ 48.42
Options granted, Weighted Average Exercise Price	28.50	37.54	42.25
Options exercised, Weighted Average Exercise Price	19.05	17.83	25.92
Options cancelled, Weighted Average Exercise Price	40.84	50.83	54.71
Options outstanding, Weighted Average Exercise Price, Ending balance	39.40	44.64	$ 47.89	$ 48.42
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 48.08	$ 44.98
Options outstanding, Weighted Average Remaining Contractual Term	7 years 6 months 25 days	7 years 3 months 3 days	7 years 5 months 15 days	7 years 5 months 15 days
Options granted, Weighted Average Remaining Contractual Term	9 years 2 months 15 days	9 years 2 months 15 days	9 years 3 months 18 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	5 years 10 months 17 days	5 years 8 months 23 days
Options outstanding, Aggregate Intrinsic Value	$ 1,650	$ 2,717	$ 3,802	$ 8,166
Options granted, Aggregate Intrinsic Value	1,343	246	205
Options exercised, Aggregate Intrinsic Value	658	383	1,636
Options cancelled, Aggregate Intrinsic Value	0	0	$ 0
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 512	$ 2,386

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net income (loss)			$ 110,122	$ (175,486)	$ 199,589
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			164,044	158,832	143,010
Amortization of debt issuance costs			11,987	10,456	9,855
Equity-based compensation expense			17,307	22,001	23,467
Deferred income taxes			1,780	(9,714)	31,372
Debt extinguishment costs				1,815	810
Legal settlements expense		$ 22,100		22,076
Loss on impairment	$ 54,400	337,900	54,386	337,889
Other			4,035	12,371	11,412
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(19,060)	(16,821)	(28,570)
Other current assets			(1,344)	13,864	20,808
Other assets			(73)	2,762	(3,176)
Accounts payable and other accrued liabilities			(21,354)	26,054	(10,113)
Accrued salaries and benefits			7,820	15,748	(8,988)
Other liabilities			3,254	(5,219)	11,794
Net cash provided by continuing operating activities			332,904	416,628	401,270
Net cash used in discontinued operating activities				(2,548)	(1,693)
Net cash provided by operating activities			332,904	414,080	399,577
Investing activities:
Cash paid for acquisitions, net of cash acquired			(45,677)		(18,191)
Cash paid for capital expenditures			(284,682)	(341,462)	(274,177)
Cash paid for real estate acquisitions			(7,618)	(18,383)	(41,057)
Settlement of foreign currency derivatives			105,008
Proceeds from sale of property and equipment			18,076	8,248	5,252
Other			13,752	(9,367)	(8,353)
Net cash used in investing activities			(201,141)	(360,964)	(336,526)
Financing activities:
Borrowings on revolving credit facility			76,573
Principal payments on revolving credit facility			(76,573)
Principal payments on long-term debt			(52,984)	(39,738)	(57,305)
Repayment of long-term debt				(21,920)
Common stock withheld for minimum statutory taxes, net			(1,649)	(3,407)	(3,455)
Distributions to noncontrolling interests			(154)
Other			(6,840)	(2,265)	686
Net cash used in financing activities			(61,627)	(67,330)	(60,074)
Effect of exchange rate changes on cash			3,546	(2,566)	7,250
Net increase (decrease) in cash and cash equivalents			73,682	(16,780)	10,227
Cash and cash equivalents at beginning of the period			50,510	67,290	57,063
Cash and cash equivalents at end of the period	124,192	50,510	124,192	50,510	67,290
Parent [Member]
Operating activities:
Net income (loss)			110,122	(175,486)	199,589
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries			(174,216)	98,669	(259,282)
Amortization of debt issuance costs			11,987	10,825	10,270
Equity-based compensation expense			17,307	22,001	23,467
Deferred income taxes			441	529	1,236
Debt extinguishment costs				940	810
Other			1,814	6,981	4,189
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets			3,929	4,596	24,549
Net cash provided by continuing operating activities			(28,616)	(30,945)	4,828
Net cash provided by operating activities			(28,616)	(30,945)	4,828
Investing activities:
Settlement of foreign currency derivatives			105,008
Net cash used in investing activities			105,008
Financing activities:
Borrowings on revolving credit facility			76,573
Principal payments on revolving credit facility			(76,573)
Principal payments on long-term debt			(52,984)	(39,738)	(57,050)
Common stock withheld for minimum statutory taxes, net			(1,649)	(3,407)	(3,455)
Other			(2,375)	(1,742)	(539)
Cash provided by (used in) intercompany activity			(19,384)	75,832	56,216
Net cash used in financing activities			(76,392)	30,945	(4,828)
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)			124,159	151,659	159,462
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			81,105	74,341	66,482
Deferred income taxes			86	(8,795)	28,882
Legal settlements expense				22,076
Loss on impairment			27,217
Other			2,100	5,457	2,498
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(13,380)	(17,328)	(21,791)
Other current assets			776	14,881	(6,429)
Other assets			(2,501)	118	(3,277)
Accounts payable and other accrued liabilities			(5,391)	15,743	4,909
Accrued salaries and benefits			4,283	15,094	(3,974)
Other liabilities			15,110	3,014	8,794
Net cash provided by continuing operating activities			233,564	276,260	235,556
Net cash used in discontinued operating activities				(2,548)	(1,693)
Net cash provided by operating activities			233,564	273,712	233,863
Investing activities:
Cash paid for acquisitions, net of cash acquired			(45,677)
Cash paid for capital expenditures			(188,161)	(210,023)	(161,312)
Cash paid for real estate acquisitions			(7,618)	(14,096)	(37,047)
Proceeds from sale of property and equipment			11,765	5,168	2,415
Other			13,752	(9,367)	(10,359)
Net cash used in investing activities			(215,939)	(228,318)	(206,303)
Financing activities:
Principal payments on long-term debt				(169)	(14,250)
Other			(1,993)	2,094	1,225
Cash provided by (used in) intercompany activity			50,840	(61,708)	16,644
Net cash used in financing activities			48,847	(59,783)	3,619
Net increase (decrease) in cash and cash equivalents			66,472	(14,389)	31,179
Cash and cash equivalents at beginning of the period			32,471	46,860	15,681
Cash and cash equivalents at end of the period	98,943	32,471	98,943	32,471	46,860
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)			50,057	(250,328)	99,820
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Depreciation and amortization			82,939	84,491	76,528
Amortization of debt issuance costs				(369)	(415)
Deferred income taxes			1,253	(1,448)	1,254
Debt extinguishment costs				875
Loss on impairment			27,169	337,889
Other			121	(67)	4,725
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(5,680)	507	(6,779)
Other current assets			(2,120)	(1,017)	27,237
Other assets			2,428	2,644	101
Accounts payable and other accrued liabilities			(15,963)	10,311	(15,022)
Accrued salaries and benefits			3,537	654	(5,014)
Other liabilities			(11,856)	(8,233)	3,000
Net cash provided by continuing operating activities			131,885	175,909	185,435
Net cash provided by operating activities			131,885	175,909	185,435
Investing activities:
Cash paid for acquisitions, net of cash acquired					(18,191)
Cash paid for capital expenditures			(96,521)	(131,439)	(112,865)
Cash paid for real estate acquisitions				(4,287)	(4,010)
Proceeds from sale of property and equipment			6,311	3,080	2,837
Other					2,006
Net cash used in investing activities			(90,210)	(132,646)	(130,223)
Financing activities:
Principal payments on long-term debt			(3,929)	(4,427)	(10,554)
Repayment of long-term debt				(21,920)
Distributions to noncontrolling interests			(154)
Other			(2,472)	(2,617)
Cash provided by (used in) intercompany activity			(31,456)	(14,124)	(72,860)
Net cash used in financing activities			(38,011)	(43,088)	(83,414)
Effect of exchange rate changes on cash			3,546	(2,566)	7,250
Net increase (decrease) in cash and cash equivalents			7,210	(2,391)	(20,952)
Cash and cash equivalents at beginning of the period			18,039	20,430	41,382
Cash and cash equivalents at end of the period	$ 25,249	$ 18,039	25,249	18,039	20,430
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)			(174,216)	98,669	(259,282)
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries			174,216	(98,669)	259,282
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets			(3,929)	(4,596)	(24,549)
Net cash provided by continuing operating activities			(3,929)	(4,596)	(24,549)
Net cash provided by operating activities			(3,929)	(4,596)	(24,549)
Financing activities:
Principal payments on long-term debt			3,929	4,596	24,549
Net cash used in financing activities			$ 3,929	$ 4,596	$ 24,549

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount					Fair Value
	December 31,					December 31,
	2019			2018		2019			2018
Amended and Restated Senior Credit Facility	$	1,668,062		$	1,715,338	$	1,668,062		$	1,715,338
6.125% Senior Notes due 2021	$	149,254		$	148,657	$	149,441		$	147,542
5.125% Senior Notes due 2022	$	297,761		$	296,946	$	299,994		$	283,583
5.625% Senior Notes due 2023	$	644,771		$	643,289	$	655,249		$	609,516
6.500% Senior Notes due 2024	$	384,430		$	383,304	$	398,366		$	369,888
Other long-term debt	$	4,821		$	5,953	$	4,821		$	5,953
Derivative instrument (liabilities) assets	$	(68,915	)	$	60,524	$	(68,915	)	$	60,524

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		12 Months Ended
	Feb. 16, 2016	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	Aug. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	Dec. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	Dec. 31, 2018 USD ($)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)
Derivative [Line Items]
Cross currency swap liabilities			$ (68,900,000)
Cross currency swap assets					$ 60,500,000
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000.0			£ 538,100,000		$ 650,000,000.0	£ 449,300,000
Terminated cross currency swap derivatives	105,000,000.0
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,965,809	$ 3,593,751
Less: accumulated depreciation	(741,775)	(485,985)
Property and equipment, net	3,224,034	3,107,766
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	448,716	430,771
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,746,111	2,423,594
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	516,769	444,538
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 254,213	$ 294,848

Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2019	Dec. 31, 2018	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at December 31, 2019 and 2018 (in thousands):

	December 31,
	2019			2018
Land	$	448,716		$	430,771
Building and improvements		2,746,111			2,423,594
Equipment		516,769			444,538
Construction in progress		254,213			294,848
		3,965,809			3,593,751
Less: accumulated depreciation		(741,775	)		(485,985	)
Property and equipment, net	$	3,224,034		$	3,107,766

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019 USD ($) Segment	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 01, 2019 USD ($)
Significant Accounting Policies [Line Items]
Maximum professional liability aggregate policy limit	$ 75,000,000.0
Professional and general liability reserve	52,600,000	$ 42,800,000
Professional and general liability reserve current	4,700,000	5,000,000.0
Professional and general liability reserve noncurrent	47,900,000	37,800,000
Insurance receivable	8,500,000	8,200,000
Insurance receivable - current portion	3,030,000	2,049,000
Insurance receivable noncurrent	5,500,000	6,100,000
Workers compensation insurance claims deductible per accident	500,000
Reserve for workers compensation liability	20,800,000	19,300,000
Accrued salaries and benefits	10,000,000.0	10,000,000.0
Other long-term liabilities	10,800,000	9,300,000
Depreciation expense	164,000,000.0	$ 158,800,000	$ 143,000,000.0
Impairment of long-lived assets	$ 54,400,000		0
Number of operating segment \| Segment	2
Number of reporting unit \| Segment	2
Intangible assets impairment charges	$ 0		$ 0
U.S. federal corporate tax rate	21.00%	21.00%	35.00%
Right-of-use assets	$ 546,207,000
Lease liabilities	581,873,000
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Right-of-use assets				$ 500,300,000
Lease liabilities				$ 526,600,000
U.K. Facilities [Member]
Significant Accounting Policies [Line Items]
Impairment of long-lived assets		$ 12,000,000.0
Intangible assets impairment charges		325,900,000
U.S. Facilities [Member]
Significant Accounting Policies [Line Items]
Intangible assets impairment charges		$ 0
Maximum [Member]
Significant Accounting Policies [Line Items]
Maximum self insured professional liability limit per claim	$ 3,000,000.0
Maximum [Member] \| Discount Rate [Member]
Significant Accounting Policies [Line Items]
Impairment of goodwill, measurement input	0.105
Maximum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life	50 years
Maximum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life	7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Maximum professional liability retention limit	$ 3,000,000.0
Minimum [Member] \| Discount Rate [Member]
Significant Accounting Policies [Line Items]
Impairment of goodwill, measurement input	0.100
Minimum [Member] \| Building and Improvements [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life	10 years
Minimum [Member] \| Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment estimated useful life	3 years

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Computation Of Basic And Diluted Earnings Per Common Share [Line Items]
Excluded common stock for computation of diluted earnings per share	2.2	1.9	1.4
Restricted Stock [Member]
Schedule Of Computation Of Basic And Diluted Earnings Per Common Share [Line Items]
Excluded common stock for computation of diluted earnings per share		0.1

Employee Benefit Plans - Summary of Components of Net Pension Plan Expense (Detail) - Pension Plan [Member] - Partnership in Care Benefits Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation	$ 1,605	$ 1,602
Expected return on assets	(2,538)	(1,319)
Net pension expense	$ (933)	$ 283

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At December 31, 2019, the Company operated 585 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the U.K. and Puerto Rico.

During 2019, the Company commenced a review of strategic alternatives including those related to its U.K. operations and a potential sale of such operations. In January 2020, the Company launched a formal process regarding the sale of its U.K. business. Consistent with market practice for U.K. transactions of this nature, and in conjunction with its advisors, the Company solicited and has received initial, non-binding offers to acquire its U.K. business from multiple bidders. The Company is now in the second phase of the sale process, during which interested bidders will receive proposed transaction documents and complete their confirmatory due diligence.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $90.4 million, $86.6 million and $76.4 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at December 31, 2019 and 2018 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	December 31, 2019		December 31, 2018		December 31, 2019			December 31, 2018
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,131		1,147		(1,131	)		(1,147	)
		3,231		3,247		(3,231	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,455		12,343		—			—
Trade names		60,831		60,109		—			—
Certificates of need		17,071		16,538		—			—
		90,357		88,990		—			—
Total	$	93,588	$	92,237	$	(3,231	)	$	(3,247	)

Leases - Schedule Of Leases On Consolidated Balance Sheet (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 501,837
Total	546,207
Finance lease liabilities	6,819
Operating lease liabilities	29,140
Finance lease liabilities	43,662
Operating lease liabilities	502,252
Total	581,873
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	44,370
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	501,837
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	6,819
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	29,140
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	43,662
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 502,252

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Combinations [Abstract]
Termination, restructuring and strategic review costs	$ 18,233	$ 16,785	$ 19,469
Management transition costs	5,529	14,033
Legal, accounting and other acquisition-related costs	3,302	3,689	4,798
Transaction-related expenses	$ 27,064	$ 34,507	$ 24,267

Financial Information for the Company and Its Subsidiaries

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

21. Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries at December 31, 2019 and 2018, and for the years ended December 31, 2019, 2018 and 2017. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	98,943	$	25,249	$	—		$	124,192
Accounts receivable, net		—		266,864		72,911		—			339,775
Other current assets		—		61,508		16,736		—			78,244
Total current assets		—		427,315		114,896		—			542,211
Property and equipment, net		—		1,313,830		1,910,204		—			3,224,034
Goodwill		—		1,992,344		456,787		—			2,449,131
Intangible assets, net		—		58,291		32,066		—			90,357
Deferred tax assets – noncurrent		1,403		—		3,339		(1,403	)		3,339
Operating lease right-of-use assets		—		97,396		404,441		—			501,837
Investment in subsidiaries		5,521,340		—		—		(5,521,340	)		—
Other assets		233,975		48,949		13,127		(227,818	)		68,233
Total assets	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142
Current liabilities:
Current portion of long-term debt	$	43,679	$	—	$	—	$	—		$	43,679
Accounts payable		—		87,165		39,880		—			127,045
Accrued salaries and benefits		—		89,483		33,069		—			122,552
Current portion of operating lease liabilities		—		17,967		11,173		—			29,140
Other accrued liabilities		33,323		22,672		85,165		—			141,160
Total current liabilities		77,002		217,287		169,287		—			463,576
Long-term debt		3,105,420		—		227,818		(227,818	)		3,105,420
Deferred tax liabilities – noncurrent		—		21,858		51,405		(1,403	)		71,860
Operating lease liabilities		—		85,365		416,887		—			502,252
Derivative instrument liabilities		68,915		—		—		—			68,915
Other liabilities		—		110,445		18,142		—			128,587
Total liabilities		3,251,337		434,955		883,539		(229,221	)		4,340,610
Redeemable noncontrolling interests		—		—		33,151		—			33,151
Total equity		2,505,381		3,503,170		2,018,170		(5,521,340	)		2,505,381
Total liabilities and equity	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	32,471	$	18,039	$	—		$	50,510
Accounts receivable, net		—		248,218		69,869		—			318,087
Other current assets		—		60,160		21,660		—			81,820
Total current assets		—		340,849		109,568		—			450,417
Property and equipment, net		—		1,219,803		1,887,963		—			3,107,766
Goodwill		—		1,936,057		460,355		—			2,396,412
Intangible assets, net		—		56,611		32,379		—			88,990
Deferred tax assets – noncurrent		1,841		—		3,468		(1,841	)		3,468
Derivative instruments		60,524		—		—		—			60,524
Investment in subsidiaries		5,190,771		—		—		(5,190,771	)		—
Other assets		306,495		52,824		9,548		(303,940	)		64,927
Total assets	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504
Current liabilities:
Current portion of long-term debt	$	34,112	$	—	$	—	$	—		$	34,112
Accounts payable		—		79,463		38,277		—			117,740
Accrued salaries and benefits		—		84,150		29,149		—			113,299
Other accrued liabilities		32,837		42,062		76,327		—			151,226
Total current liabilities		66,949		205,675		143,753		—			416,377
Long-term debt		3,159,375		—		303,940		(303,940	)		3,159,375
Deferred tax liabilities – noncurrent		—		31,874		50,339		(1,841	)		80,372
Other liabilities		—		107,866		46,401		—			154,267
Total liabilities		3,226,324		345,415		544,433		(305,781	)		3,810,391
Redeemable noncontrolling interests		—		—		28,806		—			28,806
Total equity		2,333,307		3,260,729		1,930,042		(5,190,771	)		2,333,307
Total liabilities and equity	$	5,559,631	$	3,606,144	$	2,503,281	$	(5,496,552	)	$	6,172,504

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	1,882,518	$	1,224,944		$	—			3,107,462
Salaries, wages and benefits		17,307			1,018,267		681,606			—			1,717,180
Professional fees		—			107,115		133,868			—			240,983
Supplies		—			80,137		42,924			—			123,061
Rents and leases		—			34,443		47,786			—			82,229
Other operating expenses		—			243,478		131,955			—			375,433
Depreciation and amortization		—			81,105		82,939			—			164,044
Interest expense, net		76,138			92,538		18,418			—			187,094
Loss on impairment		—			27,217		27,169			—			54,386
Transaction-related expenses		—			21,156		5,908			—			27,064
Total expenses		93,445			1,705,456		1,172,573			—			2,971,474
Income (loss) before income taxes		(93,445	)		177,062		52,371			—			135,988
Equity in earnings of subsidiaries		174,216			—		—			(174,216	)		—
(Benefit from) provision for income taxes		(29,351	)		52,903		2,314			—			25,866
Net income (loss)		110,122			124,159		50,057			(174,216	)		110,122
Net income attributable to noncontrolling interests		—			—		(1,199	)		—			(1,199	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	110,122		$	124,159	$	48,858		$	(174,216	)	$	108,923
Other comprehensive income:
Foreign currency translation loss		—			—		69,811			—			69,811
Gain on derivative instruments		(19,008	)		—		—			—			(19,008	)
Pension liability adjustment, net		—			—		(3,310	)		—			(3,310	)
Other comprehensive income (loss)		(19,008	)		—		66,501			—			47,493
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	91,114		$	124,159	$	115,359		$	(174,216	)	$	156,416

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments		Total Consolidated Amounts
Revenue	$	—		$	1,788,757	$	1,223,685		$	—		3,012,442
Salaries, wages and benefits		22,001			965,419		671,928			—		1,659,348
Professional fees		—			98,441		128,984			—		227,425
Supplies		—			76,526		42,788			—		119,314
Rents and leases		—			33,101		47,181			—		80,282
Other operating expenses		—			225,446		129,052			—		354,498
Depreciation and amortization		—			74,341		84,491			—		158,832
Interest expense, net		65,588			92,983		26,839			—		185,410
Debt extinguishment costs		940			—		875			—		1,815
Legal settlements expense		—			22,076		—			—		22,076
Loss on impairment		—			—		337,889			—		337,889
Transaction-related expenses		—			29,720		4,787			—		34,507
Total expenses		88,529			1,618,053		1,474,814			—		3,181,396
(Loss) income before income taxes		(88,529	)		170,704		(251,129	)		—		(168,954	)
Equity in earnings of subsidiaries		(98,669	)		—		—			98,669		—
(Benefit from) provision for income taxes		(11,712	)		19,045		(801	)		—		6,532
Net (loss) income		(175,486	)		151,659		(250,328	)		98,669		(175,486	)
Net income attributable to noncontrolling interests		—			—		(264	)		—		(264	)
Net (loss) income attributable to Acadia Healthcare Company, Inc.	$	(175,486	)	$	151,659	$	(250,592	)	$	98,669	$	(175,750	)
Other comprehensive income:
Foreign currency translation loss		—			—		(127,521	)		—		(127,521	)
Gain on derivative instruments		36,799			—		—			—		36,799
Pension liability adjustment, net		—			—		2,463			—		2,463
Other comprehensive income (loss)		36,799			—		(125,058	)		—		(88,259	)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$	(138,687	)	$	151,659	$	(375,650	)	$	98,669	$	(264,009	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Year Ended December 31, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	1,746,656		$	1,130,578		$	—		$	2,877,234
Provision for doubtful accounts		—			(35,636	)		(5,282	)		—			(40,918	)
Revenue		—			1,711,020			1,125,296			—			2,836,316
Salaries, wages and benefits		23,467			902,180			610,513			—			1,536,160
Professional fees		—			93,991			102,232			—			196,223
Supplies		—			75,248			39,191			—			114,439
Rents and leases		—			33,365			43,410			—			76,775
Other operating expenses		—			217,900			113,927			—			331,827
Depreciation and amortization		—			66,482			76,528			—			143,010
Interest expense, net		61,872			81,274			32,861			—			176,007
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			11,236			13,031			—			24,267
Total expenses		86,149			1,481,676			1,031,693			—			2,599,518
(Loss) income before income taxes		(86,149	)		229,344			93,603			—			236,798
Equity in earnings of subsidiaries		259,282			—			—			(259,282	)		—
(Benefit from) provision for income taxes		(26,456	)		69,882			(6,217	)		—			37,209
Net income (loss)		199,589			159,462			99,820			(259,282	)		199,589
Net loss attributable to noncontrolling interests		—			—			246			—			246
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	199,589		$	159,462		$	100,066		$	(259,282	)	$	199,835
Other comprehensive income:
Foreign currency translation gain		—			—			206,784			—			206,784
Loss on derivative instruments		(33,431	)		—			—			—			(33,431	)
Pension liability adjustment, net		—			—			2,099			—			2,099
Other comprehensive (loss) income		(33,431	)		—			208,883			—			175,452
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	166,158		$	159,462		$	308,949		$	(259,282	)	$	375,287

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net (loss) income	$	110,122		$	124,159		$	50,057		$	(174,216	)	$	110,122
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(174,216	)		—			—			174,216			—
Depreciation and amortization		—			81,105			82,939			—			164,044
Amortization of debt issuance costs		11,987			—			—			—			11,987
Equity-based compensation expense		17,307			—			—			—			17,307
Deferred income taxes		441			86			1,253			—			1,780
Loss on impairment		—			27,217			27,169			—			54,386
Other		1,814			2,100			121			—			4,035
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(13,380	)		(5,680	)		—			(19,060	)
Other current assets		—			776			(2,120	)		—			(1,344	)
Other assets		3,929			(2,501	)		2,428			(3,929	)		(73	)
Accounts payable and other accrued liabilities		—			(5,391	)		(15,963	)		—			(21,354	)
Accrued salaries and benefits		—			4,283			3,537			—			7,820
Other liabilities		—			15,110			(11,856	)		—			3,254
Net cash (used in) provided by continuing operating activities		(28,616	)		233,564			131,885			(3,929	)		332,904
Net cash used in discontinued operating activities		—			—			—			—			—
Net cash (used in) provided by operating activities		(28,616	)		233,564			131,885			(3,929	)		332,904
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(45,677	)		—			—			(45,677	)
Cash paid for capital expenditures		—			(188,161	)		(96,521	)		—			(284,682	)
Cash paid for real estate acquisitions		—			(7,618	)		—			—			(7,618	)
Settlement of foreign currency derivatives		105,008			—			—			—			105,008
Proceeds from sale of property and equipment		—			11,765			6,311			—			18,076
Other		—			13,752			—			—			13,752
Net cash used in investing activities		105,008			(215,939	)		(90,210	)		—			(201,141	)
Financing activities:
Borrowings on revolving credit facility		76,573			—			—			—			76,573
Principal payments on revolving credit facility		(76,573	)		—			—			—			(76,573	)
Principal payments on long-term debt		(52,984	)		—			(3,929	)		3,929			(52,984	)
Common stock withheld for minimum statutory taxes, net		(1,649	)		—			—			—			(1,649	)
Distributions to noncontrolling interests		—			—			(154	)		—			(154	)
Other		(2,375	)		(1,993	)		(2,472	)		—			(6,840	)
Cash provided by (used in) intercompany activity		(19,384	)		50,840			(31,456	)		—			—
Net cash provided by (used in) financing activities		(76,392	)		48,847			(38,011	)		3,929			(61,627	)
Effect of exchange rate changes on cash		—			—			3,546			—			3,546
Net decrease in cash and cash equivalents		—			66,472			7,210			—			73,682
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	98,943		$	25,249		$	—		$	124,192

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net (loss) income	$	(175,486	)	$	151,659		$	(250,328	)	$	98,669		$	(175,486	)
Adjustments to reconcile net (loss) income to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		98,669			—			—			(98,669	)		—
Depreciation and amortization		—			74,341			84,491			—			158,832
Amortization of debt issuance costs		10,825			—			(369	)		—			10,456
Equity-based compensation expense		22,001			—			—			—			22,001
Deferred income taxes		529			(8,795	)		(1,448	)		—			(9,714	)
Debt extinguishment costs		940			—			875			—			1,815
Legal settlements expense		—			22,076			—			—			22,076
Loss on impairment		—			—			337,889			—			337,889
Other		6,981			5,457			(67	)		—			12,371
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(17,328	)		507			—			(16,821	)
Other current assets		—			14,881			(1,017	)		—			13,864
Other assets		4,596			118			2,644			(4,596	)		2,762
Accounts payable and other accrued liabilities		—			15,743			10,311			—			26,054
Accrued salaries and benefits		—			15,094			654			—			15,748
Other liabilities		—			3,014			(8,233	)		—			(5,219	)
Net cash (used in) provided by continuing operating activities		(30,945	)		276,260			175,909			(4,596	)		416,628
Net cash used in discontinued operating activities		—			(2,548	)		—			—			(2,548	)
Net cash (used in) provided by operating activities		(30,945	)		273,712			175,909			(4,596	)		414,080
Investing activities:
Cash paid for capital expenditures		—			(210,023	)		(131,439	)		—			(341,462	)
Cash paid for real estate acquisitions		—			(14,096	)		(4,287	)		—			(18,383	)
Proceeds from sale of property and equipment		—			5,168			3,080			—			8,248
Other		—			(9,367	)		—			—			(9,367	)
Net cash used in investing activities		—			(228,318	)		(132,646	)		—			(360,964	)
Financing activities:
Principal payments on long-term debt		(39,738	)		(169	)		(4,427	)		4,596			(39,738	)
Repayment of long-term debt		—			—			(21,920	)		—			(21,920	)
Common stock withheld for minimum statutory taxes, net		(3,407	)		—			—			—			(3,407	)
Other		(1,742	)		2,094			(2,617	)		—			(2,265	)
Cash provided by (used in) intercompany activity		75,832			(61,708	)		(14,124	)		—			—
Net cash provided by (used in) financing activities		30,945			(59,783	)		(43,088	)		4,596			(67,330	)
Effect of exchange rate changes on cash		—			—			(2,566	)		—			(2,566	)
Net decrease in cash and cash equivalents		—			(14,389	)		(2,391	)		—			(16,780	)
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	32,471		$	18,039		$	—		$	50,510

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	199,589		$	159,462		$	99,820		$	(259,282	)	$	199,589
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(259,282	)		—			—			259,282			—
Depreciation and amortization		—			66,482			76,528			—			143,010
Amortization of debt issuance costs		10,270			—			(415	)		—			9,855
Equity-based compensation expense		23,467			—			—			—			23,467
Deferred income taxes		1,236			28,882			1,254			—			31,372
Debt extinguishment costs		810			—			—			—			810
Other		4,189			2,498			4,725			—			11,412
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(21,791	)		(6,779	)		—			(28,570	)
Other current assets		—			(6,429	)		27,237			—			20,808
Other assets		24,549			(3,277	)		101			(24,549	)		(3,176	)
Accounts payable and other accrued liabilities		—			4,909			(15,022	)		—			(10,113	)
Accrued salaries and benefits		—			(3,974	)		(5,014	)		—			(8,988	)
Other liabilities		—			8,794			3,000			—			11,794
Net cash provided by (used in) continuing operating activities		4,828			235,556			185,435			(24,549	)		401,270
Net cash used in discontinued operating activities		—			(1,693	)		—			—			(1,693	)
Net cash provided by (used in) operating activities		4,828			233,863			185,435			(24,549	)		399,577
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			—			(18,191	)		—			(18,191	)
Cash paid for capital expenditures		—			(161,312	)		(112,865	)		—			(274,177	)
Cash paid for real estate acquisitions		—			(37,047	)		(4,010	)		—			(41,057	)
Proceeds from sale of property and equipment		—			2,415			2,837			—			5,252
Other		—			(10,359	)		2,006			—			(8,353	)
Net cash used in investing activities		—			(206,303	)		(130,223	)		—			(336,526	)
Financing activities:
Principal payments on long-term debt		(57,050	)		(14,250	)		(10,554	)		24,549			(57,305	)
Common stock withheld for minimum statutory taxes, net		(3,455	)		—			—			—			(3,455	)
Other		(539	)		1,225			—			—			686
Cash provided by (used in) intercompany activity		56,216			16,644			(72,860	)		—			—
Net cash (used in) provided by financing activities		(4,828	)		3,619			(83,414	)		24,549			(60,074	)
Effect of exchange rate changes on cash		—			—			7,250			—			7,250
Net increase (decrease) in cash and cash equivalents		—			31,179			(20,952	)		—			10,227
Cash and cash equivalents at beginning of the period		—			15,681			41,382			—			57,063
Cash and cash equivalents at end of the period	$	—		$	46,860		$	20,430		$	—		$	67,290

Employee Benefit Plans - Summary of Assumptions Used to Determine Net Periodic Pension Plan Expense (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Discount rate	1.90%	2.80%
Expected long-term rate of return on plan assets	1.90%	2.80%

Revenue

12 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Revenue

3. Revenue

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 requires companies to exercise more judgment and recognize revenue using a five-step process. The Company adopted ASU 2014-09 using the modified retrospective method for all contracts effective January 1, 2018 and is using a portfolio approach to group contracts with similar characteristics and analyze historical cash collections trends. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application. Prior periods have not been adjusted. No cumulative-effect adjustment in retained earnings was recorded as the adoption of ASU 2014-09 did not significantly impact the Company’s reported historical revenue.

As a result of certain changes required by ASU 2014-09, the majority of the Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations. The adoption of ASU 2014-09 has no impact on the Company’s accounts receivable as it was historically recorded net of allowance for doubtful accounts and contractual adjustments, and the Company has eliminated the presentation of allowance for doubtful accounts on the consolidated balance sheets. At December 31, 2019 and 2018, estimated implicit price concessions of $47.4 million and $47.0 million, respectively, had been recorded as reductions to our accounts receivable balances to enable us to record our revenues and accounts receivable at the estimated amounts we expected to collect. The adoption of ASU 2014-09 did not have a significant impact on the Company’s consolidated statements of operations.

The Company evaluated the nature, amount, timing and uncertainty of revenue and cash flows using the five-step process provided within ASU 2014-09.

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor within each of the Company’s segments.

U.S. Facilities

The Company’s U.S. Facilities and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based facilities.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

Outpatient community-based facilities. Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2019		2018		2017
Acute inpatient psychiatric facilities	$	912,097	$	814,124	$	757,211
Specialty treatment facilities		788,232		761,017		725,151
Residential treatment centers		286,959		293,053		284,637
Outpatient community-based facilities		21,093		36,501		42,845
Revenue	$	2,008,381	$	1,904,695	$	1,809,844

The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the consolidated statements of operations. Bad debt expense for the years ended December 31, 2019 and 2018 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $13.7 million and $10.3 million for the years ended December 31, 2019 and 2018, respectively, and were included in other current assets in the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements resulted in a decreases to revenue of $0.4 million for the year ended December 31, 2019 and increases to revenue of $0.5 million and $0.2 million for the years ended December 31, 2018 and 2017, respectively.

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The cost of providing charity care services were $4.3 million, $4.7 million and $5.3 million for the years ended December 31, 2019, 2018 and 2017, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities for the years ended December 31, 2019, 2018 and 2017 (in thousands):

	Year Ended December 31,
	2019					2018					2017
	Amount		%			Amount		%			Amount			%
Commercial	$	565,350		28.2	%	$	573,089		30.1	%	$	569,242			30.8	%
Medicare		294,691		14.7	%		280,340		14.7	%		281,270			15.2	%
Medicaid		1,007,102		50.1	%		893,644		46.9	%		796,375			43.0	%
Self-Pay		118,716		5.9	%		134,054		7.1	%		169,727			9.2	%
Other		22,522		1.1	%		23,568		1.2	%		33,942			1.8	%
Revenue before provision for doubtful accounts		2,008,381		100.0	%		1,904,695		100.0	%		1,850,556			100.0	%
Provision for doubtful accounts		—					—					(40,712	)
Revenue	$	2,008,381				$	1,904,695				$	1,809,844

U.K. Facilities

The Company’s U.K. Facilities and services provided by the U.K. Facilities can generally be classified into the following categories: healthcare facilities, education and children’s services; and adult care facilities.

Healthcare facilities. Healthcare facilities provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient.

Education and children’s services. Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require 52-week residential care to support complex and challenging behavior and fostering services.

Adult care facilities. Adult care focuses on care of individuals with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. It also includes long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia. Care is provided in a number of settings, including in residential care homes and through supported living.

The table below presents total U.K. revenue attributed to each category (in thousands):

	Year Ended December 31,
	2019		2018		2017
Healthcare facilities	$	607,053	$	614,994	$	566,482
Education and Children’s Services		183,195		187,306		165,874
Adult Care facilities		308,833		305,447		294,116
Revenue	$	1,099,081	$	1,107,747	$	1,026,472

The Company receives payments from approximately 500 public funded sources in the U.K. (including the National Health Service (“NHS”), Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales) and individual patients and clients. The Company determines the transaction price based on established billing rates by payor and is reduced by implicit price concessions. Implicit price concessions are insignificant in our U.K. Facilities. There is no significant variable consideration in our U.K. Facilities’ contracts. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities for the years ended December 31, 2019, 2018 and 2017 (in thousands):

	Year Ended December 31,
	2019					2018					2017
	Amount		%			Amount		%			Amount			%
U.K. public funded sources	$	991,353		90.2	%	$	1,000,828		90.3	%	$	922,159			89.8	%
Self-Pay		105,430		9.6	%		104,824		9.5	%		95,687			9.3	%
Other		2,298		0.2	%		2,095		0.2	%		8,832			0.9	%
Revenue before provision for doubtful accounts		1,099,081		100.0	%		1,107,747		100.0	%		1,026,678			100.0	%
Provision for doubtful accounts		—					—					(206	)
Revenue	$	1,099,081				$	1,107,747				$	1,026,472

The Company’s contract liabilities primarily consist of unearned revenue in our U.K. Facilities due to the timing of payments received mainly in our education and children’s services and healthcare facilities. Contract liabilities are included in other accrued liabilities on the consolidated balance sheets. A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2018	$	31,239
Payments received		172,666
Revenue recognized		(167,811	)
Foreign currency translation loss		485
Balance at December 31, 2019	$	36,579

Noncontrolling Interests (Tables)

12 Months Ended

Dec. 31, 2019

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2018	$	22,417
Acquisition of redeemable noncontrolling interests		6,125
Net income attributable to noncontrolling interests		264
Balance at December 31, 2018		28,806
Acquisition of redeemable noncontrolling interests		3,300
Net income attributable to noncontrolling interests		1,199
Distributions to noncontrolling interests		(154	)
Balance at December 31, 2019	$	33,151

Income Taxes - Summary of Domestic and Foreign Components of Income (Loss) before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Income (loss) before income taxes	$ (10,248)	$ 49,560	$ 59,805	$ 36,871	$ (341,336)	$ 55,036	$ 69,258	$ 48,088	$ 135,988	$ (168,954)	$ 236,798
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Income (loss) before income taxes									61,921	(228,350)	120,905
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Income (loss) before income taxes									$ 74,067	$ 59,396	$ 115,893

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
Senior notes maturity year	2024	2024

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	484,111	360,909	273,599
Granted, Number of Units	234,408	285,358	219,840
Cancelled, Number of Units	(271,162)	(89,173)
Vested, Number of Units		(72,983)	(132,530)
Unvested, Number of Shares/Units, Ending balance	447,357	484,111	360,909
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 44.52	$ 50.04	$ 59.68
Granted, Weighted Average Grant-Date Fair Value	34.54	42.26	43.23
Cancelled, Weighted Average Grant-Date Fair Value	45.17	55.44
Vested, Weighted Average Grant-Date Fair Value		49.64	58.67
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 38.89	$ 44.52	$ 50.04

Quarterly Information (Unaudited) - Schedule of Quarterly Financial Information (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Provisional tax benefits related to Tax Act			$ 10,500
Loss on impairment	$ 54,400	$ 337,900		$ 54,386	$ 337,889
Legal settlements expense		$ 22,100			$ 22,076

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) $ in Thousands	Dec. 31, 2019 USD ($)
Finance Leases
2020	$ 7,494
2021	35,624
2022	2,681
2023	1,369
2024	1,007
Thereafter	25,088
Total minimum lease payments	73,263
Less: amount of lease payments representing interest	22,782
Present value of future minimum lease payments	50,481
Less: Current portion of lease liabilities	6,819
Noncurrent lease liabilities	43,662
Operating Leases
2020	61,857
2021	58,279
2022	53,395
2023	49,714
2024	47,505
Thereafter	689,931
Total minimum lease payments	960,681
Less: amount of lease payments representing interest	429,289
Present value of future minimum lease payments	531,392
Current portion of operating lease liabilities	29,140
Operating lease liabilities	$ 502,252